uric acid has been researched along with Fatty Liver, Nonalcoholic in 171 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease." | 8.93 | Uric acid in metabolic syndrome: From an innocent bystander to a central player. ( Jensen, T; Johnson, RJ; Kanbay, M; Lanaspa, MA; Le, M; Nakagawa, T; Rivard, C; Roncal-Jimenez, C; Solak, Y, 2016) |
| "An excess circulating uric acid level, even within the normal range, is always comorbid with metabolic syndrome (MS), several of its components, and nonalcoholic fatty liver disease (NAFLD), which was regarded as hepatic manifestation of MS; however, these associations remain controversial." | 8.91 | Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. ( Li, X; Sun, L; Yang, Z; Yu, C; Yuan, H; Zhang, Z; Zhao, C; Zhu, X, 2015) |
| "Emerging evidence has shown that serum uric acid (SUA) elevation might cause metabolic derangements, including metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD); however, magnitude of the risk has not been quantified." | 8.91 | Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies. ( Liu, Z; Que, S; Zheng, S; Zhou, L, 2015) |
| "The association between serum uric acid (SUA) and mortality from cardiovascular diseases (CVDs) in nonalcoholic fatty liver disease (NAFLD) participants remains uncertain." | 8.31 | Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease. ( He, P; Li, H; Liu, C; Liu, M; Qin, X; Wu, Q; Yang, S; Ye, Z; Zhang, Y; Zhang, Z; Zhou, C, 2023) |
| " We investigated whether uric acid (UA) and the macrophage marker soluble form of cysteine scavenger receptor CD163 (sCD163) can be used as biomarkers for deteriorated metabolism or pediatric MAFLD in children with overweight or obesity." | 8.31 | Uric acid and sCD163 as biomarkers for metabolic dysfunction and MAFLD in children and adolescents with overweight and obesity. ( Dalstrup Jakobsen, D; Kristensen, NM; Meldgaard Bruun, J; Orry, S, 2023) |
| "To study the associations of non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and serum uric acid (SUA) in patients with post-myocardial infarction (MI) patients, and the relationship of SUA with 12-year mortality risk." | 8.31 | Serum uric acid is related to liver and kidney disease and 12-year mortality risk after myocardial infarction. ( Boersma, E; Geleijnse, JM; Heerkens, L; Kardys, I; van Westing, AC; Voortman, T, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) and serum uric acid (SUA) levels are risk factors for developing cardiovascular disease (CVD)." | 8.12 | The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. ( Hwang, J; Kang, K; Kim, K; Lee, JM; Sheol, H; Shin, J; Sim, Y; Yang, T, 2022) |
| "Increasing evidence has supported that serum uric acid (SUA), alanine aminotransferase (ALT) and waist circumference (WC) are associated with the occurrence of non-alcoholic fatty liver disease (NAFLD)." | 8.12 | A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. ( Chen, Y; Ding, Y; Fan, H; Tang, Z; Wang, H; Wang, J; Wang, M; Zhang, L; Zhang, R; Zhang, W, 2022) |
| "Serum uric acid (SUA) and heavy metals are closely related to non-alcoholic fatty liver disease (NAFLD)." | 8.12 | Conjunctional Relationship between Serum Uric Acid and Serum Nickel with Non-Alcoholic Fatty Liver Disease in Men: A Cross-Sectional Study. ( Jiang, J; Liu, C; Liu, W; Wang, Y; Wu, W; Yang, Z; Zhang, G, 2022) |
| " Additionally, anthropometric parameters (height, weight, BMI, waist circumference, hip circumference) such as lab data including lipid profile (triglycerides, HDL, LDL), liver function parameters (ALT, AST), uric acid, glucose metabolism (fasting insulin and glucagon, HbA1c, glucose 120 min) and indices evaluating insulin resistance (HIRI, SPISE, HOMA-IR, WBISI) were measured." | 8.12 | Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease. ( Ahlström, H; Bergsten, P; Forslund, A; Kullberg, J; Manell, H; Mangge, H; Maruszczak, K; Mörwald, K; Pixner, T; Radzikowski, K; Schütz, S; Weghuber, D, 2022) |
| "The Uric acid to HDL cholesterol ratio of the Non-alcoholic fatty liver disease (13±5%) group was significantly higher compared to the Uric acid to HDL cholesterol ratio of the control (10±4%) group (p<0." | 8.02 | The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. ( Aktas, G; Bilgin, S; Demirkol, ME; Duman, TT; Kahveci, G; Kosekli, MA; Kurtkulagii, O; Tel, BMA, 2021) |
| "d-fagomine counteracts sucrose-induced steatosis and hypertension, presumably by reducing the postprandial levels of fructose in the liver." | 7.96 | The Buckwheat Iminosugar d-Fagomine Attenuates Sucrose-Induced Steatosis and Hypertension in Rats. ( Amézqueta, S; Atienza, L; Casas, J; Hereu, M; Medina, I; Miralles-Pérez, B; Muñoz, S; Ramos-Romero, S; Romeu, M; Torres, JL, 2020) |
| "It is unclear the role of longitudinal trajectory of serum uric acid (SUA) on the development of non-alcoholic fatty liver disease (NAFLD)." | 7.96 | Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. ( Guo, X; Kang, X; Li, H; Ma, Z; Tao, L; Xu, C; Yang, X; Zhang, S; Zheng, D, 2020) |
| "Previous studies found elevated serum uric acid (SUA) was associated with the development or progression of non-alcoholic fatty liver disease (NAFLD) in general population; in this study we aim to investigate the association of SUA and the severity of NAFLD based on grade of fatty liver on ultrasonography in non-obese subjects." | 7.85 | Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. ( Chen, H; Gong, L; Luo, R; Peng, B; Ren, W; Wang, Y; Zheng, X, 2017) |
| "The causal relationship between serum uric acid (SUA) level and non-alcoholic fatty liver disease (NAFLD) has not yet been clarified." | 7.81 | Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults: the Cardiometabolic Risk in Chinese (CRC) study. ( Dou, LJ; Gong, Y; Liang, J; Liu, XK; Pei, Y; Qi, L; Qiu, QQ; Yang, MQ; Zou, CY, 2015) |
| "Increased serum uric acid (SUA) levels may be involved in the development of non-alcoholic fatty liver disease (NAFLD) in men presenting with metabolic syndrome (MetS) and/or insulin resistance." | 7.79 | Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. ( Gao, Y; Hu, Y; Huang, Z; Li, L; Li, Z; Liang, Z; Liao, M; Lu, Z; Mo, Z; Peng, T; Qin, X; Shi, D; Sun, Y; Tan, A; Wang, M; Wu, C; Xie, Y; Yang, X; Zhang, H; Zhang, S; Zhang, Y, 2013) |
| "The aim of this study was to compare serum uric acid values in two ethnically distinct Chinese populations: Uyghur, with a high prevalence of nonalcoholic fatty liver disease, and Han, with a lower prevalence." | 7.79 | Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China. ( Cai, W; Miao, L; Sun, YP; Wu, X; Yao, H; Zhang, B; Zou, Y, 2013) |
| "Experimental and observational studies suggest a role for uric acid in non-alcoholic fatty liver disease (NAFLD)." | 7.79 | Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. ( Chonchol, M; Jalal, DI; Johnson, RJ; McFann, K; Sirota, JC; Targher, G, 2013) |
| "The objective of the present study was to determine the relationship between serum uric acid (SUA) level and the presence of nonalcoholic fatty liver disease (NAFLD)." | 7.77 | The relationship between normal serum uric acid and nonalcoholic fatty liver disease. ( Ahn, HY; Hwang, IC; Suh, AR; Suh, SY, 2011) |
| "Curcumin is a dietary natural product with beneficial metabolic effects relevant to the treatment of NAFLD." | 6.82 | Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. ( Jafari, R; Kianpour, P; Mohtashami, R; Panahi, Y; Sahebkar, A; Simental-Mendía, LE, 2016) |
| "Atorvastatin, which has proven safe in NAFLD/NASH, reduces SUA levels, ameliorates NAFLD/NASH, prevents liver fibrosis, and above all substantially reduces CVD morbidity and mortality in comparison with those on statins but without NAFLD/NASH." | 6.58 | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? ( Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A, 2018) |
| "non-alcoholic fatty liver disease (NAFLD) is known to be associated with some metabolic disorders." | 6.55 | Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis. ( Darmawan, G; Hamijoyo, L; Hasan, I, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major, worldwide public health problem." | 6.53 | Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. ( Braddock, M; Liu, WY; Lu, QD; Shi, KQ; Song, D; Sun, DQ; Wu, SJ; Zheng, MH; Zhu, GQ, 2016) |
| "The risk of NAFLD seemed more pronounced among women (OR 1." | 6.53 | High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. ( Fan, Y; Wei, F; Zhou, Y, 2016) |
| "We modeled the relationship between NAFLD and relevant demographic, anthropometric, and biochemical variables." | 5.91 | The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population. ( Pirola, CJ; Sookoian, S, 2023) |
| "The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide." | 5.91 | Association between serum ferritin and uric acid levels and nonalcoholic fatty liver disease in the Chinese population. ( He, X; Liu, D; Tian, H; Tian, L; Ye, Y; Zhou, F, 2023) |
| "Observational studies have shown that nonalcoholic fatty liver disease (NAFLD) is highly correlated with serum uric acid (SUA)." | 5.72 | Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease: A 2-Sample Bidirectional Mendelian Randomization Study. ( Cui, J; Fu, Y; Li, H; Li, S; Liu, M; Liu, Y; Tian, L; Zhang, X; Zhuo, L, 2022) |
| "Allopurinol treatment significantly reduced hepatic steatosis, epididymal fat, serum UA, HOMA-IR, hepatic enzyme levels, and cholesterol in the OLETF-HFrD-Allo group." | 5.62 | Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. ( Ahn, KJ; Cho, IJ; Chung, HY; Hwang, YC; Jeong, IK; Jeong, SW; Lee, SH; Lim, SJ; Moon, JY; Oh, DH; Yoo, J, 2021) |
| "Obesity has been demonstrated to show a consistent link with the increased possibility of nonalcoholic fatty liver disease (NAFLD)." | 5.62 | Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. ( Chen, S; Jiao, Y; Ma, X; Shi, H; Sun, X; Wu, S; Xing, J; Yang, R; Zhang, Q; Zhang, S, 2021) |
| "However, the pathogenesis of NAFLD, especially how non-alcoholic fatty liver progress to non-alcoholic steatohepatitis, is still unclear." | 5.56 | Exosomal miRNAs Profile in Children's Nonalcoholic Fatty Liver Disease and the Correlation with Transaminase and Uric Acid. ( Dong, G; Fu, J; Huang, K; Jia, J; Liang, X; Lin, H; Ni, Y; Peng, W; Wu, W; Yuan, J; Zhou, X, 2020) |
| "The presence or absence of NAFLD was assessed by abdominal ultrasonography." | 5.56 | Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Nonobese Postmenopausal Women: A Cross-sectional Study. ( Bao, T; Du, J; Gao, W; Gong, L; Huang, Y; Ji, G; Jiang, X; Li, Z; Tang, H; Yang, H; Ying, Z, 2020) |
| "The levels of SUA in subjects with NAFLD in the menstrual period, menopause transition period, and postmenopause were 268." | 5.51 | Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease according to Different Menstrual Status Groups. ( Ai, P; Chen, X; Chen, Y; Ding, G; Feng, X; Huang, Q; Ji, L; Li, D; Li, Y; Liu, H; Wang, X; Xu, X; Zhou, Y, 2019) |
| "Uric acid is an endogenous danger signal and activator of the inflammasome, and has been independently associated with an increased risk of cirrhosis." | 5.51 | Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). ( Aller, R; Ampuero, J; Andrade, RJ; Aspichueta, P; Buque, X; Burgos-Santamaría, D; Fernández Rodríguez, CM; Gómez-Camarero, J; Gutiérrez García, ML; Hernández-Guerra, M; Latorre, M; Martín-Mateos, RMª; Romero-Gómez, M; Rosales, JM, 2019) |
| "The target of theacrine's activities on NAFLD is identified as SIRT3." | 5.48 | Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism. ( Gong, L; He, RR; Hong, M; Kurihara, H; Li, YF; Tian, JY; Wang, GE; Wu, YP; Yao, N; Zhai, YJ, 2018) |
| "Hyperuricemia is associated with metabolic syndrome (MetS), but the association is often confounded by the shared background of obesity." | 5.46 | Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. ( Du, T; Li, M; Lin, X; Lu, H; Yu, X; Zhang, S, 2017) |
| "There was an obvious increase in both NAFLD prevalence (26." | 5.43 | Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Wang, AP; Yu, TP; Zhao, CC; Zhu, Y, 2016) |
| "Furthermore, the prevalence rate of NAFLD increased progressively across the sex-specific SUA tertiles only in men (37." | 5.43 | Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. ( Fan, N; Peng, L; Peng, Y; Wang, Y; Xia, Z; Zhang, L, 2016) |
| "In the present study, 841 NAFLD males (30-75 years) were recruited from a Chinese prospective cohort study (PMMJS) and followed up for five years." | 5.43 | Associations between Serum Uric Acid and the Remission of Non-Alcoholic Fatty Liver Disease in Chinese Males. ( Dong, C; Guo, Z; Liu, C; Qiu, J; Song, K; Wang, Y; Xu, Y; Zhang, B; Zhou, H; Zhou, Z, 2016) |
| "The prevalence rates of NAFLD were 71." | 5.43 | Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. ( Chen, N; He, CM; Li, X; Li, Z; Liu, CQ; Liu, S; Liu, Y; Shi, X; Wang, D; Yan, B; Yang, S; Zeng, X, 2016) |
| "The prevalence of NAFLD was higher in participants with higher SUA levels (10." | 5.42 | Association between serum uric acid and nonalcoholic fatty liver disease in the US population. ( Bonekamp, S; Clark, JM; Hernaez, R; Lazo, M; Liu, SH; Shih, MH, 2015) |
| "The association between sUA and NAFLD was significantly greater in females than in males." | 5.42 | Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. ( Braddock, M; Chen, YP; Huang, WJ; Kong, FQ; Lin, L; Shi, KQ; Wu, SJ; Ye, BZ; Zheng, MH; Zheng, ZX; Zhu, GQ; Zou, H, 2015) |
| "The risk factors for T2DM patients with NAFLD are mainly BMI, WHR, TG, and SUA." | 5.42 | The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid. ( Li, YL; Mei, CX; Musha, H; Wang, HJ; Wulasihan, M; Xie, H; Xing, Y, 2015) |
| "To investigate the prevalence of nonalcoholic fatty liver disease (NAFLD) and the association of serum uric acid level with NAFLD in Uygur people, Xinjiang." | 5.40 | The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. ( Cai, W; Song, JM; Sun, YP; Yao, H; Zhang, B; Zhang, YX, 2014) |
| "Hyperuricemia is a common finding in patients with NAFLD and is independently associated with early histological findings in this clinically relevant condition." | 5.40 | The relationship of serum uric acid with non-alcoholic fatty liver disease. ( Celebi, G; Dogru, T; Ercin, CN; Genc, H; Gurel, H; Kara, M; Kayadibi, H; Sertoglu, E, 2014) |
| "The prevalence of NAFLD among Chinese postmenopausal women with normal SUA was 32." | 5.40 | [Relationship between normal serum uric acid levels and nonalcoholic fatty liver disease in postmenopausal women]. ( Chen, Y; Liu, P; Lou, H; Ma, F; Zhu, Y, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is an emerging health problem worldwide." | 5.39 | Relationship between serum uric acid level and nonalcoholic fatty liver disease in pre- and postmenopausal women. ( Moon, SS, 2013) |
| "Although many studies have indicated a relationship between nonalcoholic fatty liver disease (NAFLD) and hyperuricemia, a few studies specifically examining the effects of the severity of liver fat content (LFC) on serum uric acid (SUA) and the presence of hyperuricemia because of the limitation of the examination methods for NAFLD." | 5.20 | Liver Fat Content Is Associated with Elevated Serum Uric Acid in the Chinese Middle-Aged and Elderly Populations: Shanghai Changfeng Study. ( Gao, X; Li, Q; Li, X; Lin, H; Liu, X; Ma, H; Pan, B; Wang, D; Wu, J; Xia, M; Zhao, N, 2015) |
| " Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial." | 5.16 | Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. ( Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R, 2012) |
| " Fructose overconsumption may result in insulin resistance, oxidative stress, inflammation, elevated uric acid levels, increased blood pressure, and increased triglyceride concentrations in both the blood and liver." | 5.12 | Fructose and the Liver. ( López-Sánchez, P; Muriel, P; Ramos-Tovar, E, 2021) |
| "Experimental and observational studies suggest a role for increased uric acid in non-alcoholic fatty liver disease (NAFLD)." | 4.95 | Serum uric acid levels in non-alcoholic steatosis patients: a meta-analysis. ( Fang, H; Geng, X; Huang, F; Liu, A, 2017) |
| "Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders." | 4.93 | Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. ( Xu, C, 2016) |
| "Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease." | 4.93 | Uric acid in metabolic syndrome: From an innocent bystander to a central player. ( Jensen, T; Johnson, RJ; Kanbay, M; Lanaspa, MA; Le, M; Nakagawa, T; Rivard, C; Roncal-Jimenez, C; Solak, Y, 2016) |
| "An excess circulating uric acid level, even within the normal range, is always comorbid with metabolic syndrome (MS), several of its components, and nonalcoholic fatty liver disease (NAFLD), which was regarded as hepatic manifestation of MS; however, these associations remain controversial." | 4.91 | Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. ( Li, X; Sun, L; Yang, Z; Yu, C; Yuan, H; Zhang, Z; Zhao, C; Zhu, X, 2015) |
| "Emerging evidence has shown that serum uric acid (SUA) elevation might cause metabolic derangements, including metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD); however, magnitude of the risk has not been quantified." | 4.91 | Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies. ( Liu, Z; Que, S; Zheng, S; Zhou, L, 2015) |
| "Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk." | 4.87 | Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2011) |
| "The association between serum uric acid (SUA) and mortality from cardiovascular diseases (CVDs) in nonalcoholic fatty liver disease (NAFLD) participants remains uncertain." | 4.31 | Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease. ( He, P; Li, H; Liu, C; Liu, M; Qin, X; Wu, Q; Yang, S; Ye, Z; Zhang, Y; Zhang, Z; Zhou, C, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease that is related to high serum uric acid; however, the association between the frequency of gout flares and NAFLD risk remains unclear." | 4.31 | The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study. ( Chen, Y; Chi, J; Dong, B; Liu, C; Si, K; Wang, Y; Xu, L, 2023) |
| " In the stratified analysis by uric acid levels, the prevalence of NAFLD was significantly higher in participants with MHO, MUNW, and MUO in the hyperuricemia group than those in the normal uric acid group, and the interaction effect of metabolic phenotypes and uric acid on NAFLD was statistical significant (P < 0." | 4.31 | Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. ( Li, X; Miao, Y; Zhang, Q; Zhang, Y; Zheng, J, 2023) |
| " We investigated whether uric acid (UA) and the macrophage marker soluble form of cysteine scavenger receptor CD163 (sCD163) can be used as biomarkers for deteriorated metabolism or pediatric MAFLD in children with overweight or obesity." | 4.31 | Uric acid and sCD163 as biomarkers for metabolic dysfunction and MAFLD in children and adolescents with overweight and obesity. ( Dalstrup Jakobsen, D; Kristensen, NM; Meldgaard Bruun, J; Orry, S, 2023) |
| "Overall, the XO inhibitor febuxostat exerted protective effects against NASH and atherosclerosis in SHRSP5/Dmcr rats." | 4.31 | Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats. ( Fujii, M; Fukuoka, T; Hirohata, S; Honma, K; Kakimoto, M; Kirihara, S; Kitamori, K; Nakayama, H; Ran, S; Sato, I; Watanabe, S; Yamamoto, S, 2023) |
| "To study the associations of non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and serum uric acid (SUA) in patients with post-myocardial infarction (MI) patients, and the relationship of SUA with 12-year mortality risk." | 4.31 | Serum uric acid is related to liver and kidney disease and 12-year mortality risk after myocardial infarction. ( Boersma, E; Geleijnse, JM; Heerkens, L; Kardys, I; van Westing, AC; Voortman, T, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) and serum uric acid (SUA) levels are risk factors for developing cardiovascular disease (CVD)." | 4.12 | The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. ( Hwang, J; Kang, K; Kim, K; Lee, JM; Sheol, H; Shin, J; Sim, Y; Yang, T, 2022) |
| "Increasing evidence has supported that serum uric acid (SUA), alanine aminotransferase (ALT) and waist circumference (WC) are associated with the occurrence of non-alcoholic fatty liver disease (NAFLD)." | 4.12 | A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. ( Chen, Y; Ding, Y; Fan, H; Tang, Z; Wang, H; Wang, J; Wang, M; Zhang, L; Zhang, R; Zhang, W, 2022) |
| " Hyperuricemia was diagnosed as fasting serum uric acid > 420 µmol/L in men and women." | 4.12 | Association between circulating cystatin C and hyperuricemia: a cross-sectional study. ( Chen, Y; Guo, Y; Huang, H; Shen, C; Xu, C, 2022) |
| "Serum uric acid (SUA) and heavy metals are closely related to non-alcoholic fatty liver disease (NAFLD)." | 4.12 | Conjunctional Relationship between Serum Uric Acid and Serum Nickel with Non-Alcoholic Fatty Liver Disease in Men: A Cross-Sectional Study. ( Jiang, J; Liu, C; Liu, W; Wang, Y; Wu, W; Yang, Z; Zhang, G, 2022) |
| "The association between the serum uric acid (sUA) to creatinine ratio (sUA/Cr) and non-alcoholic fatty liver disease (NAFLD) has not been sufficiently clarified." | 4.12 | Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States. ( Chen, X; Qian, G; Shi, G; Wang, L; Wang, R; Xue, F; Yang, N, 2022) |
| " Additionally, anthropometric parameters (height, weight, BMI, waist circumference, hip circumference) such as lab data including lipid profile (triglycerides, HDL, LDL), liver function parameters (ALT, AST), uric acid, glucose metabolism (fasting insulin and glucagon, HbA1c, glucose 120 min) and indices evaluating insulin resistance (HIRI, SPISE, HOMA-IR, WBISI) were measured." | 4.12 | Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease. ( Ahlström, H; Bergsten, P; Forslund, A; Kullberg, J; Manell, H; Mangge, H; Maruszczak, K; Mörwald, K; Pixner, T; Radzikowski, K; Schütz, S; Weghuber, D, 2022) |
| "The Uric acid to HDL cholesterol ratio of the Non-alcoholic fatty liver disease (13±5%) group was significantly higher compared to the Uric acid to HDL cholesterol ratio of the control (10±4%) group (p<0." | 4.02 | The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. ( Aktas, G; Bilgin, S; Demirkol, ME; Duman, TT; Kahveci, G; Kosekli, MA; Kurtkulagii, O; Tel, BMA, 2021) |
| "d-fagomine counteracts sucrose-induced steatosis and hypertension, presumably by reducing the postprandial levels of fructose in the liver." | 3.96 | The Buckwheat Iminosugar d-Fagomine Attenuates Sucrose-Induced Steatosis and Hypertension in Rats. ( Amézqueta, S; Atienza, L; Casas, J; Hereu, M; Medina, I; Miralles-Pérez, B; Muñoz, S; Ramos-Romero, S; Romeu, M; Torres, JL, 2020) |
| "It is unclear the role of longitudinal trajectory of serum uric acid (SUA) on the development of non-alcoholic fatty liver disease (NAFLD)." | 3.96 | Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. ( Guo, X; Kang, X; Li, H; Ma, Z; Tao, L; Xu, C; Yang, X; Zhang, S; Zheng, D, 2020) |
| " After adjustment for age, sex, body mass index (BMI), alanine aminotransferase (ALT), uric acid (UA), total bilirubin (TB), fasting plasma glucose (FPG) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), the OR for tertile 3 (OR = 1." | 3.96 | Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study. ( Lu, G; Miao, L; Xu, C; Xue, Z; Yang, S; Ye, M; Zhong, J; Zhou, X, 2020) |
| "To investigate the diagnostic role of combined salivary uric acid (UA), glucose and insulin levels to screen noninvasively for metabolic syndrome (MetS) and nonalcoholic fatty liver disease." | 3.91 | Salivary markers of hepato-metabolic comorbidities in pediatric obesity. ( Belmonte, F; Bisogno, A; Cavallo, P; Guercio Nuzio, S; Landolfi, A; Lausi, O; Marciano, F; Pierri, L; Troisi, J; Vajro, P, 2019) |
| " The fast food-type pattern was further associated with higher levels of C-reactive protein and uric acid and the unsaturated fatty acid pattern with reduced levels of insulin and homeostatic model assessment of insulin resistance (P < 0." | 3.91 | Dietary patterns and non-alcoholic fatty liver disease in a Greek case-control study. ( Borsa, D; Dedoussis, GV; Dimitriou, M; Kalafati, IP; Kokkinos, A; Revenas, K, 2019) |
| " Classical (fasting glucose, TGL, HDL, blood pressure) and non classical (insulin resistance [HOMA-IR], creatinine, AST, ALT, uric acid, fibrinogen, liver US and 24h BP profile) risk factors were compared between groups with and without MS." | 3.88 | Shall we diagnose metabolic syndrome in adolescents? ( Janus, D; Ruszała, A; Starzyk, JB; Szczudlik, E; Sztefko, K; Wójcik, M, 2018) |
| "Epidemiological evidence suggests sex difference in serum uric acid (SUA) and alanine aminotransferase (ALT) might be a potential explanation for the gender difference in prevalence of non-alcoholic fatty liver disease (NAFLD)." | 3.88 | Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study. ( Li, D; Li, X; Liu, F; Ma, Q; Song, X; Wang, X; Yang, H; Zhang, X, 2018) |
| "Previous studies found elevated serum uric acid (SUA) was associated with the development or progression of non-alcoholic fatty liver disease (NAFLD) in general population; in this study we aim to investigate the association of SUA and the severity of NAFLD based on grade of fatty liver on ultrasonography in non-obese subjects." | 3.85 | Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. ( Chen, H; Gong, L; Luo, R; Peng, B; Ren, W; Wang, Y; Zheng, X, 2017) |
| "Serum uric acid (SUA) is a new therapeutic target for non-alcoholic fatty liver disease (NAFLD)." | 3.85 | A rapid and high-throughput method for the determination of serum uric acid based on microarray technology and nanomaterial. ( Bai, Y; Feng, F; Li, X; Zhang, Z, 2017) |
| "Nonalcoholic fatty liver disease patients had significantly lower IGF-1 standard deviation score (IGF-1 SDS) and higher body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) and uric acid levels than the control group." | 3.85 | Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents. ( Cheng, X; Hu, Y; Li, G; Liang, S; Song, R, 2017) |
| "Subject age and measurements of liver enzymes, γ- glutamyl transpeptidase (γGT), uric acid, high-density lipoprotein cholesterol, and insulin resistance were significantly different between the non-NAFLD group and NAFLD group." | 3.83 | Insulin resistance, body composition, and fat distribution in obese children with nonalcoholic fatty liver disease. ( Chang, EJ; Yang, HR, 2016) |
| "The causal relationship between serum uric acid (SUA) level and non-alcoholic fatty liver disease (NAFLD) has not yet been clarified." | 3.81 | Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults: the Cardiometabolic Risk in Chinese (CRC) study. ( Dou, LJ; Gong, Y; Liang, J; Liu, XK; Pei, Y; Qi, L; Qiu, QQ; Yang, MQ; Zou, CY, 2015) |
| "Elevated serum uric acid levels reflect and also cause both oxidative stress and insulin resistance and are frequently observed in patients with the metabolic syndrome." | 3.81 | The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. ( Ben-Assuli, O; Chodick, G; Goldstein, A; Magid, A; Rabinowich, L; Shalev, V; Shibolet, O; Zelber-Sagi, S, 2015) |
| " There were positive correlations between NAFLD and insulin resistance index (HOMA-IR), free fatty acids (FFA), tumor necrosis factor-α (TNF-α), omentin-1, visceral fat area, homocysteine (HCY), and serum uric acid (UA)." | 3.81 | Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. ( Di, F; Gao, L; Jia, G; Li, N; Li, Q; Shao, J; Wang, L; Wang, Q, 2015) |
| "Serum uric acid levels have been reported to be associated with non-alcoholic fatty liver disease (NAFLD)." | 3.80 | Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. ( Chen, Y; Liu, PJ; Lou, HP; Ma, F; Zhu, YN, 2014) |
| "Serum uric acid levels are significantly associated with nonalcoholic fatty liver disease (NAFLD)." | 3.80 | The significance of serum xanthine oxidoreductase in patients with nonalcoholic fatty liver disease. ( Chen, Y; Xu, C; Zhang, J; Zhao, Y, 2014) |
| " Thus, application of ursodeoxycholic acid, rosuvastatin and allopurinol in these study patients with NAFLD dosages in combination with hyperuricemia improves the clinical symptoms and normalization of biochemical parameters and normalizes the spectrum of biliary acids." | 3.80 | [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA]. ( Barabanchyk, OV; Kozak, NP; Svintsits'kyĭ, AS, 2014) |
| "Increased serum uric acid (SUA) levels may be involved in the development of non-alcoholic fatty liver disease (NAFLD) in men presenting with metabolic syndrome (MetS) and/or insulin resistance." | 3.79 | Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. ( Gao, Y; Hu, Y; Huang, Z; Li, L; Li, Z; Liang, Z; Liao, M; Lu, Z; Mo, Z; Peng, T; Qin, X; Shi, D; Sun, Y; Tan, A; Wang, M; Wu, C; Xie, Y; Yang, X; Zhang, H; Zhang, S; Zhang, Y, 2013) |
| "The aim of this study was to compare serum uric acid values in two ethnically distinct Chinese populations: Uyghur, with a high prevalence of nonalcoholic fatty liver disease, and Han, with a lower prevalence." | 3.79 | Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China. ( Cai, W; Miao, L; Sun, YP; Wu, X; Yao, H; Zhang, B; Zou, Y, 2013) |
| "Experimental and observational studies suggest a role for uric acid in non-alcoholic fatty liver disease (NAFLD)." | 3.79 | Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. ( Chonchol, M; Jalal, DI; Johnson, RJ; McFann, K; Sirota, JC; Targher, G, 2013) |
| "The objective of the present study was to determine the relationship between serum uric acid (SUA) level and the presence of nonalcoholic fatty liver disease (NAFLD)." | 3.77 | The relationship between normal serum uric acid and nonalcoholic fatty liver disease. ( Ahn, HY; Hwang, IC; Suh, AR; Suh, SY, 2011) |
| " In this line recent studies observed an independent link between higher uric acid serum levels and clinical diagnosis of non-alcoholic fatty liver disease (NAFLD)." | 3.77 | Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. ( Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Petta, S, 2011) |
| "Hepatic inflammation is prevalent in several metabolic liver diseases." | 2.82 | The contribution of sterile inflammation to the fatty liver disease and the potential therapies. ( Shaker, ME, 2022) |
| "Curcumin is a dietary natural product with beneficial metabolic effects relevant to the treatment of NAFLD." | 2.82 | Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. ( Jafari, R; Kianpour, P; Mohtashami, R; Panahi, Y; Sahebkar, A; Simental-Mendía, LE, 2016) |
| "Atorvastatin, which has proven safe in NAFLD/NASH, reduces SUA levels, ameliorates NAFLD/NASH, prevents liver fibrosis, and above all substantially reduces CVD morbidity and mortality in comparison with those on statins but without NAFLD/NASH." | 2.58 | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? ( Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome; its rising prevalence parallels the rise in obesity and diabetes." | 2.58 | Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. ( Abdelmalek, MF; Diehl, AM; Green, M; Jensen, T; Johnson, RJ; Kang, DH; Kuwabara, M; Lanaspa, MA; Nadeau, KJ; Nakagawa, T; Roncal, C; Rosen, HR; Sanchez-Lozada, LG; Sato, Y; Sullivan, S; Tolan, DR, 2018) |
| "Hyperuricemia is a significant risk factor for nonalcoholic fatty liver disease (NAFLD)." | 2.55 | Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. ( Ahuja, W; Jaruvongvanich, V; Ungprasert, P; Wijarnpreecha, K; Wirunsawanya, K, 2017) |
| "non-alcoholic fatty liver disease (NAFLD) is known to be associated with some metabolic disorders." | 2.55 | Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis. ( Darmawan, G; Hamijoyo, L; Hasan, I, 2017) |
| "The risk of NAFLD in subjects with hyperuricaemia was significantly higher than subjects with normal uric acid level with the pooled odds ratio (OR) of 1." | 2.55 | Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( Cheungpasitporn, W; Lekuthai, N; Panjawatanan, P; Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017) |
| "Uric acid is a natural antioxidant." | 2.55 | Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. ( Ahuja, W; Jaruvongvanich, V; Ungprasert, P; Wijarnpreecha, K, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major, worldwide public health problem." | 2.53 | Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. ( Braddock, M; Liu, WY; Lu, QD; Shi, KQ; Song, D; Sun, DQ; Wu, SJ; Zheng, MH; Zhu, GQ, 2016) |
| "Hyperuricemia is associated with an increased risk of NAFLD in Asian populations." | 2.53 | Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. ( Gong, S; Song, J; Wang, L; Wang, Y; Zhang, S, 2016) |
| "The risk of NAFLD seemed more pronounced among women (OR 1." | 2.53 | High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. ( Fan, Y; Wei, F; Zhou, Y, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD), tightly linked to the metabolic syndrome (MS), has emerged as a leading cause of chronic liver disease worldwide." | 2.53 | Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. ( Fargion, S; Lombardi, R; Pisano, G, 2016) |
| "NAFLD was assessed using the Fibrosis-4 (Fib-4) index." | 1.91 | Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. ( Lipsky, PE; Rustgi, VK; Schlesinger, N; Yeo, AE, 2023) |
| "We modeled the relationship between NAFLD and relevant demographic, anthropometric, and biochemical variables." | 1.91 | The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population. ( Pirola, CJ; Sookoian, S, 2023) |
| "Abdominal obesity is the strongest risk factor for type 2 diabetes in lean nonalcoholic fatty liver disease." | 1.91 | Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period. ( Chang, M; Li, D; Li, N; Tan, H; Wu, S; Xang, W; Xie, C; Zhang, MY, 2023) |
| "A total of 175 adult patients with NAFLD diagnosed by abdominal ultrasonography were included in this study." | 1.91 | Association of neck circumference-related indices with metabolic, atherogenic and liver function biomarkers in patients with non-alcoholic fatty liver disease: a cross-sectional study. ( Arefhosseini, S; Arefhosseini, SR; Ebrahimi-Mameghani, M; Tavakkoli, S; Tutunchi, H, 2023) |
| "The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide." | 1.91 | Association between serum ferritin and uric acid levels and nonalcoholic fatty liver disease in the Chinese population. ( He, X; Liu, D; Tian, H; Tian, L; Ye, Y; Zhou, F, 2023) |
| "In this study, type 2 diabetes (T2D), sex, and menopausal status were combined to refine the stratification of obesity regarding the risk of advanced SLD and gain further insight into disease physiopathology." | 1.91 | Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study. ( Baud, G; Bauvin, P; Caiazzo, R; Chatelain, E; Chetboun, M; Gnemmi, V; Lasailly, G; Lefebvre, P; Legendre, B; Leteurtre, E; Marciniak, C; Marot, G; Mathurin, P; Oukhouya-Daoud, N; Pattou, F; Raverdy, V; Staels, B; Vandel, J; Vantyghem, MC; Verkindt, H, 2023) |
| "Observational studies have shown that nonalcoholic fatty liver disease (NAFLD) is highly correlated with serum uric acid (SUA)." | 1.72 | Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease: A 2-Sample Bidirectional Mendelian Randomization Study. ( Cui, J; Fu, Y; Li, H; Li, S; Liu, M; Liu, Y; Tian, L; Zhang, X; Zhuo, L, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) share common pathogenic mechanisms and risk factors." | 1.72 | The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population. ( Chen, Y; Chi, J; Huang, Y; Lv, W; Wang, Y; Zhou, Y, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease." | 1.72 | Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence. ( Guo, X; Halengbieke, A; Han, Y; Kong, L; Li, Q; Ni, X; Tao, L; Tong, C; Wu, Z; Yang, X; Zhang, S; Zheng, D, 2022) |
| "The lean/normal-weight NAFLD−non-MAFLD patients with higher SUA levels are still at high risk of severe steatosis." | 1.72 | The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease. ( Chen, Y; Feng, S; He, J; Sun, Y; Ye, J; Zhong, B, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are two pathologies that intersect each other." | 1.72 | Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population. ( Catanzaro, R; He, F; Marotta, F; Sciuto, M; Singh, B, 2022) |
| "Independent risk factors of NAFLD were identified by multivariate logistic regression analysis." | 1.62 | A nomogram for discrimination of non-alcoholic fatty liver disease in patients with chronic hepatitis B. ( Cao, D; Chen, Y; Han, Q; Li, C; Li, N; Liu, Z; Wang, X; Zhang, P, 2021) |
| "The odds of NAFLD were increasingly higher from the second to the fourth quartile of SUA as compared to the lowest quartile." | 1.62 | Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. ( Cui, Y; Hu, W; Liu, J; Shi, H; Song, L; Zhao, Q, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease with few therapeutic options available currently." | 1.62 | Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. ( Chen, L; Han, R; Hong, Y; Li, B; Li, H; Ma, J; Qiu, H; Sheng, L; Wu, G; Zheng, N; Zhong, J, 2021) |
| "The diagnosis of NAFLD was according to the clinical diagnosis of the guidelines." | 1.62 | Study on the independent effect of thyroid hormone based on uric acid level on NAFLD. ( Chao, G; Chen, L, 2021) |
| "Allopurinol treatment significantly reduced hepatic steatosis, epididymal fat, serum UA, HOMA-IR, hepatic enzyme levels, and cholesterol in the OLETF-HFrD-Allo group." | 1.62 | Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. ( Ahn, KJ; Cho, IJ; Chung, HY; Hwang, YC; Jeong, IK; Jeong, SW; Lee, SH; Lim, SJ; Moon, JY; Oh, DH; Yoo, J, 2021) |
| "Obesity has been demonstrated to show a consistent link with the increased possibility of nonalcoholic fatty liver disease (NAFLD)." | 1.62 | Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. ( Chen, S; Jiao, Y; Ma, X; Shi, H; Sun, X; Wu, S; Xing, J; Yang, R; Zhang, Q; Zhang, S, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) commonly occurs in patients with type 2 diabetes mellitus (T2DM)." | 1.56 | Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. ( Chen, W; He, M; Li, S; Liu, D; Long, M; Peng, J; Wang, C; Yang, G; Zhang, L, 2020) |
| "Background The prevalence of childhood obesity and its related comorbidities in Malaysia are alarming." | 1.56 | Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity. ( Anuar Zaini, A; Jalaludin, MY; Mohamed, RZ, 2020) |
| "Hyperuricemia is a major risk for non-alcoholic fatty liver disease." | 1.56 | Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis. ( Chen, D; Chen, S; Wang, J; Wang, X; Xu, C; Yang, H, 2020) |
| "However, the pathogenesis of NAFLD, especially how non-alcoholic fatty liver progress to non-alcoholic steatohepatitis, is still unclear." | 1.56 | Exosomal miRNAs Profile in Children's Nonalcoholic Fatty Liver Disease and the Correlation with Transaminase and Uric Acid. ( Dong, G; Fu, J; Huang, K; Jia, J; Liang, X; Lin, H; Ni, Y; Peng, W; Wu, W; Yuan, J; Zhou, X, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity." | 1.56 | Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese. ( Chen, G; Chen, XH; He, H; Kuang, Y; Lin, BY; Wu, LM; Zheng, SS, 2020) |
| "The presence or absence of NAFLD was assessed by abdominal ultrasonography." | 1.56 | Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Nonobese Postmenopausal Women: A Cross-sectional Study. ( Bao, T; Du, J; Gao, W; Gong, L; Huang, Y; Ji, G; Jiang, X; Li, Z; Tang, H; Yang, H; Ying, Z, 2020) |
| "The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has increased and NAFLD is not always recognized in individuals with metabolic syndrome (MS)." | 1.56 | Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. ( Hirao, A; Kagemoto, K; Kida, Y; Kurihara, T; Nakasono, M; Okahisa, T; Okamoto, K; Okazaki, J; Sogabe, M; Takayama, T; Takehara, M; Tanaka, H; Taniguchi, T; Tomonari, T, 2020) |
| "(1) In retired persons, prevalence of NAFLD was greater in females (81." | 1.56 | Correlation between income and non-alcoholic fatty liver disease in a Chinese population. ( Fan, YQ; Hao, HR; Hu, W; Liu, Z; Ni, YJ; Shao, XJ; Wang, XQ; Wen, SR; Wu, XJ; Yu, WN, 2020) |
| "The levels of SUA in subjects with NAFLD in the menstrual period, menopause transition period, and postmenopause were 268." | 1.51 | Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease according to Different Menstrual Status Groups. ( Ai, P; Chen, X; Chen, Y; Ding, G; Feng, X; Huang, Q; Ji, L; Li, D; Li, Y; Liu, H; Wang, X; Xu, X; Zhou, Y, 2019) |
| "We recruited 1527 adult patients with NAFLD who completed a comprehensive health checkup." | 1.51 | The severity of NAFLD is associated with the risk of urolithiasis. ( Qin, S; Wang, J; Wang, S; Wang, X; Xu, Y; Zhang, Y; Zhou, C, 2019) |
| "Uric acid is an endogenous danger signal and activator of the inflammasome, and has been independently associated with an increased risk of cirrhosis." | 1.51 | Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). ( Aller, R; Ampuero, J; Andrade, RJ; Aspichueta, P; Buque, X; Burgos-Santamaría, D; Fernández Rodríguez, CM; Gómez-Camarero, J; Gutiérrez García, ML; Hernández-Guerra, M; Latorre, M; Martín-Mateos, RMª; Romero-Gómez, M; Rosales, JM, 2019) |
| "Hyperuricemia is a risk factor for nonalcoholic fatty liver disease (NAFLD), however, the effect of gender on the hyperuricemia-related NAFLD development remains unclear." | 1.51 | Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. ( Bao, J; Cai, Z; Fu, X; Li, Y; Li, Z; Miao, L; Qiao, L; Xu, K; Zhao, X, 2019) |
| "Elderly obese patients with NAFLD are at a higher risk of CKD." | 1.51 | Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease. ( Bian, J; Chen, F; Jin, D; Li, H; Luo, K; Wang, J; Wang, Q, 2019) |
| "A cohort of 6310 initially NAFLD-free participants was enrolled in this prospective study." | 1.48 | Risk for the development of non-alcoholic fatty liver disease: A prospective study. ( Chen, S; Li, Y; Ma, L; Miao, M; Wang, J; Xu, C; Xu, L; Yu, C, 2018) |
| "NAFLD was determined by hepatic ultrasonography, then its clinical features were analyzed and its associated risk factors evaluated." | 1.48 | Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. ( Chen, MY; Jia, WP; Li, LX; Li, TT; Lu, JX; Tang, ZH; Wang, AP; Zhao, CC, 2018) |
| "Although MS and NAFLD were more prevalent in adolescents, young children also demonstrated MS and NAFLD as obesity-related complications." | 1.48 | Biochemical Predictors of Early Onset Non-Alcoholic Fatty Liver Disease in Young Children with Obesity. ( Cho, J; Kim, JY; Yang, HR, 2018) |
| "The target of theacrine's activities on NAFLD is identified as SIRT3." | 1.48 | Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism. ( Gong, L; He, RR; Hong, M; Kurihara, H; Li, YF; Tian, JY; Wang, GE; Wu, YP; Yao, N; Zhai, YJ, 2018) |
| "Atrial fibrillation and nonalcoholic fatty liver disease are two pathological conditions that are highly prevalent worldwide and share multiple CVD risk factors." | 1.48 | Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. ( Li, P; Liu, Y; Miao, M; Pan, Y; Xu, C; Xu, L; Zhang, Y; Zhu, Z, 2018) |
| "Hyperuricemia is associated with metabolic syndrome (MetS), but the association is often confounded by the shared background of obesity." | 1.46 | Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. ( Du, T; Li, M; Lin, X; Lu, H; Yu, X; Zhang, S, 2017) |
| "There was a significant association in NAFLD found in males, compared with females (Wald = 118." | 1.46 | Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study. ( Shen, XM; Shu, L; Yu, XL; Zhang, XY; Zheng, PF, 2017) |
| "Obese children with NAFLD were studied (n=271)." | 1.46 | Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. ( Alisi, A; Byrne, CD; Crudele, A; De Vito, R; Mosca, A; Nobili, V; Scorletti, E; Villani, A, 2017) |
| "123 participants who had NAFLD at baseline lost NAFLD during the 8-year follow-up period." | 1.43 | Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. ( Chen, XH; Li, YL; Lu, ZY; Shao, Z; Wulasihan, M, 2016) |
| "There was an obvious increase in both NAFLD prevalence (26." | 1.43 | Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Wang, AP; Yu, TP; Zhao, CC; Zhu, Y, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and correlated with obesity." | 1.43 | Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. ( Guo, J; Lu, J; Wang, L, 2016) |
| "Furthermore, the prevalence rate of NAFLD increased progressively across the sex-specific SUA tertiles only in men (37." | 1.43 | Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. ( Fan, N; Peng, L; Peng, Y; Wang, Y; Xia, Z; Zhang, L, 2016) |
| "In the present study, 841 NAFLD males (30-75 years) were recruited from a Chinese prospective cohort study (PMMJS) and followed up for five years." | 1.43 | Associations between Serum Uric Acid and the Remission of Non-Alcoholic Fatty Liver Disease in Chinese Males. ( Dong, C; Guo, Z; Liu, C; Qiu, J; Song, K; Wang, Y; Xu, Y; Zhang, B; Zhou, H; Zhou, Z, 2016) |
| "The prevalence rates of NAFLD were 71." | 1.43 | Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. ( Chen, N; He, CM; Li, X; Li, Z; Liu, CQ; Liu, S; Liu, Y; Shi, X; Wang, D; Yan, B; Yang, S; Zeng, X, 2016) |
| "Children with histologically proven NAFLD, and obese and lean controls received oral fructose (1 g kg(-1) ideal body weight)." | 1.42 | Oral fructose absorption in obese children with non-alcoholic fatty liver disease. ( Johnson, RJ; Le, MT; Love-Osborne, K; Pan, Z; Rivard, C; Robbins, K; Sokol, RJ; Sullivan, JS; Sundaram, SS, 2015) |
| "The prevalence of NAFLD in light drinkers was significantly lower than in non-drinkers, and supporting previous reports studying the general population, LAC is one of the significant predictors of a decreased prevalence of NAFLD in men with MS." | 1.42 | Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome. ( Nakasono, M; Okahisa, T; Sogabe, M; Takayama, T; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T, 2015) |
| "Hyperuricemia is a common feature of patients with non-alcoholic fatty liver disease (NAFLD)." | 1.42 | Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. ( Dooley, S; Li, Y; Miao, M; Sun, Y; Wan, X; Weng, H; Xu, C; Xu, G; Xu, L; Yan, M; Yu, C, 2015) |
| "The prevalence of NAFLD was higher in participants with higher SUA levels (10." | 1.42 | Association between serum uric acid and nonalcoholic fatty liver disease in the US population. ( Bonekamp, S; Clark, JM; Hernaez, R; Lazo, M; Liu, SH; Shih, MH, 2015) |
| "The association between sUA and NAFLD was significantly greater in females than in males." | 1.42 | Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. ( Braddock, M; Chen, YP; Huang, WJ; Kong, FQ; Lin, L; Shi, KQ; Wu, SJ; Ye, BZ; Zheng, MH; Zheng, ZX; Zhu, GQ; Zou, H, 2015) |
| "NAFLD is closely correlated with baPWV, particularly in females." | 1.42 | Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity. ( Chen, JH; Chen, LY; Dai, HL; Fang, LZ; Lu, CR; Qiao, QH; Zhu, WH, 2015) |
| "Whether nonalcoholic fatty liver disease (NAFLD) is related to vitamin D and bone health in obese children is unknown." | 1.42 | Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease. ( Chang, EJ; Yang, HR; Yi, DY, 2015) |
| "The risk factors for T2DM patients with NAFLD are mainly BMI, WHR, TG, and SUA." | 1.42 | The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid. ( Li, YL; Mei, CX; Musha, H; Wang, HJ; Wulasihan, M; Xie, H; Xing, Y, 2015) |
| "To investigate the prevalence of nonalcoholic fatty liver disease (NAFLD) and the association of serum uric acid level with NAFLD in Uygur people, Xinjiang." | 1.40 | The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. ( Cai, W; Song, JM; Sun, YP; Yao, H; Zhang, B; Zhang, YX, 2014) |
| "Hyperuricemia is a common finding in patients with NAFLD and is independently associated with early histological findings in this clinically relevant condition." | 1.40 | The relationship of serum uric acid with non-alcoholic fatty liver disease. ( Celebi, G; Dogru, T; Ercin, CN; Genc, H; Gurel, H; Kara, M; Kayadibi, H; Sertoglu, E, 2014) |
| "The prevalence of NAFLD among Chinese postmenopausal women with normal SUA was 32." | 1.40 | [Relationship between normal serum uric acid levels and nonalcoholic fatty liver disease in postmenopausal women]. ( Chen, Y; Liu, P; Lou, H; Ma, F; Zhu, Y, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) affects 9." | 1.40 | Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. ( Behling, C; Donithan, M; Hallinan, EK; Newton, KP; Schwimmer, JB; Tonascia, J; Xanthakos, SA; Zepeda, A, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is an emerging health problem worldwide." | 1.39 | Relationship between serum uric acid level and nonalcoholic fatty liver disease in pre- and postmenopausal women. ( Moon, SS, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children in the United States." | 1.38 | Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. ( Belt, P; Colvin, R; Lavine, JE; Molleston, JP; Murray, KF; Rosenthal, P; Schwimmer, JB; Tonascia, J; Unalp, A; Vos, MB, 2012) |
| "Patients with NAFLD had significantly lower levels of serum-free thyroxine (FT4) than controls (11·12 ± 1·43 vs 11·58 ± 1·47 pmol/l; P < 0·001)." | 1.37 | Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. ( Li, Y; Miao, M; Xu, C; Xu, L; Yu, C, 2011) |
| " In addition, there was a dose-response relationship between SU and NAFLD in subjects with and without gout." | 1.36 | Gout and risk of non-alcoholic fatty liver disease. ( Chang, HC; Chen, HW; Chiu, CT; Hwang, JS; Ko, YS; Kuo, CF; Luo, SF; See, LC; Tseng, WY; Yu, KH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 104 (60.82) | 24.3611 |
| 2020's | 67 (39.18) | 2.80 |
| Authors | Studies |
|---|---|
| Kosekli, MA | 1 |
| Kurtkulagii, O | 1 |
| Kahveci, G | 1 |
| Duman, TT | 1 |
| Tel, BMA | 1 |
| Bilgin, S | 1 |
| Demirkol, ME | 1 |
| Aktas, G | 1 |
| Yang, Y | 3 |
| Qu, Y | 2 |
| Lv, X | 1 |
| Zhao, R | 1 |
| Yu, J | 1 |
| Hu, S | 1 |
| Kang, J | 2 |
| Zhang, Y | 11 |
| Gong, Y | 2 |
| Cui, T | 1 |
| Zhang, X | 10 |
| Yan, Y | 1 |
| Kim, K | 1 |
| Kang, K | 1 |
| Sheol, H | 1 |
| Shin, J | 1 |
| Sim, Y | 1 |
| Yang, T | 3 |
| Hwang, J | 1 |
| Lee, JM | 1 |
| Wang, M | 3 |
| Zhang, R | 2 |
| Zhang, L | 6 |
| Ding, Y | 2 |
| Tang, Z | 1 |
| Fan, H | 1 |
| Wang, H | 3 |
| Zhang, W | 1 |
| Chen, Y | 16 |
| Wang, J | 12 |
| Shaker, ME | 1 |
| Schlesinger, N | 1 |
| Rustgi, VK | 1 |
| Yeo, AE | 1 |
| Lipsky, PE | 1 |
| Guo, Y | 1 |
| Huang, H | 2 |
| Shen, C | 1 |
| Xu, C | 14 |
| Li, S | 3 |
| Fu, Y | 2 |
| Liu, Y | 8 |
| Li, H | 9 |
| Tian, L | 2 |
| Zhuo, L | 1 |
| Liu, M | 2 |
| Cui, J | 2 |
| Huang, Y | 4 |
| Zhou, Y | 3 |
| Wang, Y | 11 |
| Chi, J | 2 |
| Lv, W | 1 |
| Zhu, W | 1 |
| Liang, A | 1 |
| Shi, P | 1 |
| Yuan, S | 1 |
| Zhu, Y | 4 |
| Fu, J | 2 |
| Zheng, T | 1 |
| Wen, Z | 2 |
| Wu, X | 3 |
| Sookoian, S | 1 |
| Pirola, CJ | 1 |
| Liu, C | 8 |
| Liu, W | 1 |
| Zhang, G | 1 |
| Jiang, J | 2 |
| Yang, Z | 2 |
| Wu, W | 3 |
| Wang, R | 1 |
| Xue, F | 2 |
| Wang, L | 5 |
| Shi, G | 1 |
| Qian, G | 1 |
| Yang, N | 2 |
| Chen, X | 4 |
| Tong, C | 1 |
| Li, Q | 5 |
| Kong, L | 1 |
| Ni, X | 1 |
| Halengbieke, A | 1 |
| Zhang, S | 8 |
| Wu, Z | 1 |
| Tao, L | 3 |
| Han, Y | 2 |
| Zheng, D | 3 |
| Guo, X | 4 |
| Yang, X | 7 |
| Yang, S | 4 |
| Ye, Z | 1 |
| Wu, Q | 2 |
| Zhou, C | 2 |
| Zhang, Z | 3 |
| He, P | 1 |
| Qin, X | 2 |
| He, J | 1 |
| Ye, J | 2 |
| Sun, Y | 4 |
| Feng, S | 1 |
| Zhong, B | 1 |
| Maruszczak, K | 1 |
| Radzikowski, K | 1 |
| Schütz, S | 1 |
| Mangge, H | 1 |
| Bergsten, P | 1 |
| Forslund, A | 1 |
| Manell, H | 1 |
| Pixner, T | 1 |
| Ahlström, H | 1 |
| Kullberg, J | 1 |
| Mörwald, K | 1 |
| Weghuber, D | 1 |
| Hamed, MA | 1 |
| Akhigbe, RE | 1 |
| Aremu, AO | 1 |
| Odetayo, AF | 1 |
| Sun, D | 4 |
| Tang, C | 3 |
| Zhao, Q | 6 |
| Qin, Y | 3 |
| Zhang, J | 8 |
| Ferro, Y | 1 |
| Maurotti, S | 1 |
| Mazza, E | 1 |
| Pujia, R | 1 |
| Sciacqua, A | 1 |
| Musolino, V | 1 |
| Mollace, V | 1 |
| Pujia, A | 1 |
| Montalcini, T | 1 |
| Theofilis, P | 1 |
| Vordoni, A | 1 |
| Tsimihodimos, V | 1 |
| Kalaitzidis, RG | 1 |
| Si, K | 1 |
| Xu, L | 6 |
| Dong, B | 1 |
| Zheng, J | 2 |
| Li, X | 17 |
| Miao, Y | 1 |
| Zhang, Q | 4 |
| Chen, S | 6 |
| Wang, X | 12 |
| Zhai, H | 1 |
| Fan, WH | 1 |
| Zhu, T | 1 |
| Xu, G | 2 |
| Liao, W | 2 |
| Liang, XS | 1 |
| Li, CZ | 1 |
| Hwang, SM | 1 |
| Cho, KY | 1 |
| Orry, S | 1 |
| Dalstrup Jakobsen, D | 1 |
| Kristensen, NM | 1 |
| Meldgaard Bruun, J | 1 |
| Yu, C | 5 |
| Zhou, X | 5 |
| Wang, T | 2 |
| Zhu, L | 1 |
| Zhou, W | 1 |
| Bao, H | 1 |
| Cheng, X | 2 |
| Feng, Y | 1 |
| Zheng, S | 2 |
| Liu, L | 4 |
| Kakimoto, M | 1 |
| Fujii, M | 1 |
| Sato, I | 1 |
| Honma, K | 1 |
| Nakayama, H | 1 |
| Kirihara, S | 1 |
| Fukuoka, T | 1 |
| Ran, S | 1 |
| Hirohata, S | 1 |
| Kitamori, K | 1 |
| Yamamoto, S | 1 |
| Watanabe, S | 1 |
| Li, N | 4 |
| Xang, W | 1 |
| Wu, S | 2 |
| Li, D | 5 |
| Chang, M | 1 |
| Xie, C | 1 |
| Zhang, MY | 1 |
| Tan, H | 2 |
| Choi, J | 1 |
| Joe, H | 1 |
| Oh, JE | 1 |
| Cho, YJ | 1 |
| Shin, HS | 1 |
| Heo, NH | 1 |
| Wang, YY | 1 |
| Chen, B | 2 |
| Wang, N | 1 |
| Zhang, TJ | 1 |
| Jiang, YG | 1 |
| Wu, YL | 1 |
| He, N | 1 |
| Zhao, GM | 1 |
| Liu, X | 3 |
| Shi, A | 1 |
| Deng, J | 2 |
| Ma, J | 2 |
| Yang, L | 1 |
| Tantai, X | 1 |
| Wang, Q | 6 |
| Chang, D | 2 |
| Lu, X | 2 |
| Shi, H | 3 |
| Wang, Z | 2 |
| Niu, H | 1 |
| Deng, Q | 1 |
| Xia, S | 1 |
| Arefhosseini, S | 1 |
| Tutunchi, H | 1 |
| Tavakkoli, S | 1 |
| Arefhosseini, SR | 1 |
| Ebrahimi-Mameghani, M | 1 |
| Tao, M | 1 |
| Liu, J | 2 |
| He, M | 2 |
| Chen, W | 4 |
| Wang, C | 5 |
| Heerkens, L | 1 |
| van Westing, AC | 1 |
| Voortman, T | 1 |
| Kardys, I | 1 |
| Boersma, E | 1 |
| Geleijnse, JM | 1 |
| Zhou, F | 1 |
| He, X | 2 |
| Liu, D | 2 |
| Ye, Y | 1 |
| Tian, H | 1 |
| Raverdy, V | 1 |
| Chatelain, E | 1 |
| Lasailly, G | 1 |
| Caiazzo, R | 1 |
| Vandel, J | 1 |
| Verkindt, H | 1 |
| Marciniak, C | 1 |
| Legendre, B | 1 |
| Bauvin, P | 1 |
| Oukhouya-Daoud, N | 1 |
| Baud, G | 1 |
| Chetboun, M | 1 |
| Vantyghem, MC | 1 |
| Gnemmi, V | 1 |
| Leteurtre, E | 1 |
| Staels, B | 1 |
| Lefebvre, P | 1 |
| Mathurin, P | 1 |
| Marot, G | 1 |
| Pattou, F | 1 |
| Abe, T | 1 |
| Miyazaki, M | 1 |
| Ishihara, T | 1 |
| Kanezaki, S | 1 |
| Notani, N | 1 |
| Kataoka, M | 1 |
| Tsumura, H | 1 |
| Peng, J | 1 |
| Long, M | 1 |
| Yang, G | 1 |
| Sotoudehmanesh, R | 1 |
| Tahmasbi, A | 1 |
| Sadeghi, A | 1 |
| Hosseini, H | 1 |
| Mohamadnejad, M | 1 |
| Ramos-Romero, S | 1 |
| Hereu, M | 1 |
| Atienza, L | 1 |
| Amézqueta, S | 1 |
| Casas, J | 1 |
| Muñoz, S | 1 |
| Medina, I | 1 |
| Miralles-Pérez, B | 1 |
| Romeu, M | 1 |
| Torres, JL | 1 |
| Huang, Q | 1 |
| Ai, P | 1 |
| Liu, H | 2 |
| Xu, X | 2 |
| Ding, G | 1 |
| Li, Y | 12 |
| Feng, X | 2 |
| Ji, L | 1 |
| Mohamed, RZ | 1 |
| Jalaludin, MY | 1 |
| Anuar Zaini, A | 1 |
| Chen, D | 2 |
| Yang, H | 4 |
| Cao, D | 1 |
| Li, C | 2 |
| Zhang, P | 2 |
| Han, Q | 1 |
| Liu, Z | 5 |
| Huang, K | 1 |
| Jia, J | 1 |
| Ni, Y | 1 |
| Yuan, J | 1 |
| Liang, X | 1 |
| Lin, H | 2 |
| Peng, W | 1 |
| Dong, G | 1 |
| Ma, Z | 2 |
| Kang, X | 2 |
| Wu, LM | 1 |
| He, H | 1 |
| Chen, G | 3 |
| Kuang, Y | 2 |
| Lin, BY | 1 |
| Chen, XH | 2 |
| Zheng, SS | 1 |
| Nakagawa, T | 4 |
| Johnson, RJ | 6 |
| Andres-Hernando, A | 2 |
| Roncal-Jimenez, C | 2 |
| Sanchez-Lozada, LG | 3 |
| Tolan, DR | 2 |
| Lanaspa, MA | 4 |
| Brennan, P | 1 |
| Clare, K | 1 |
| George, J | 1 |
| Dillon, JF | 1 |
| Catanzaro, R | 1 |
| Sciuto, M | 1 |
| He, F | 1 |
| Singh, B | 1 |
| Marotta, F | 1 |
| Bao, T | 1 |
| Ying, Z | 1 |
| Gong, L | 3 |
| Du, J | 1 |
| Ji, G | 1 |
| Li, Z | 6 |
| Gao, W | 2 |
| Jiang, X | 2 |
| Tang, H | 1 |
| Lukenda Zanko, V | 1 |
| Domislovic, V | 1 |
| Trkulja, V | 1 |
| Krznaric-Zrnic, I | 1 |
| Turk-Wensveen, T | 1 |
| Krznaric, Z | 1 |
| Filipec Kanizaj, T | 1 |
| Radic-Kristo, D | 1 |
| Bilic-Zulle, L | 1 |
| Orlic, L | 1 |
| Dinjar-Kujundzic, P | 1 |
| Poropat, G | 1 |
| Stimac, D | 1 |
| Hauser, G | 1 |
| Mikolasevic, I | 1 |
| Sogabe, M | 3 |
| Okahisa, T | 3 |
| Kurihara, T | 1 |
| Takehara, M | 1 |
| Kagemoto, K | 1 |
| Okazaki, J | 1 |
| Kida, Y | 1 |
| Hirao, A | 1 |
| Tanaka, H | 3 |
| Tomonari, T | 3 |
| Taniguchi, T | 3 |
| Okamoto, K | 1 |
| Nakasono, M | 3 |
| Takayama, T | 3 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 2 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 4 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 2 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 2 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xiang, Y | 1 |
| Zhou, L | 3 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 2 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 2 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 4 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Chen, L | 5 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 2 |
| Zhang, E | 1 |
| Deng, L | 1 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 1 |
| Li, J | 8 |
| Li, P | 2 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, W | 1 |
| Wang, S | 4 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 2 |
| Ahmad, NH | 1 |
| Zhu, J | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Yao, H | 3 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Hu, W | 3 |
| Lu, J | 3 |
| Li, M | 2 |
| Li, W | 2 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Wei, Y | 2 |
| Gao, Y | 3 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Zhang, M | 4 |
| Zhang, H | 2 |
| Dong, Y | 1 |
| Xu, Y | 3 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liang, C | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 2 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 2 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 2 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 3 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 2 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Guan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Ye, C | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 2 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 2 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 2 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 2 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Wu, J | 2 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 2 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 2 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 3 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 2 |
| Cao, T | 1 |
| Guo, L | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 2 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 3 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 2 |
| Hou, G | 1 |
| Xie, H | 2 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 2 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 2 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Sun, C | 1 |
| Hao, HR | 1 |
| Yu, WN | 1 |
| Wang, XQ | 1 |
| Shao, XJ | 1 |
| Wu, XJ | 1 |
| Wen, SR | 1 |
| Fan, YQ | 1 |
| Ni, YJ | 1 |
| Zhong, J | 2 |
| Ye, M | 1 |
| Miao, L | 3 |
| Lu, G | 1 |
| Xue, Z | 1 |
| Zhou, M | 1 |
| Xing, X | 1 |
| Hu, C | 1 |
| Song, L | 1 |
| Han, R | 1 |
| Qiu, H | 1 |
| Zheng, N | 1 |
| Hong, Y | 1 |
| Sheng, L | 1 |
| Chao, G | 1 |
| Cho, IJ | 1 |
| Oh, DH | 1 |
| Yoo, J | 1 |
| Hwang, YC | 1 |
| Ahn, KJ | 1 |
| Chung, HY | 1 |
| Jeong, SW | 1 |
| Moon, JY | 1 |
| Lee, SH | 1 |
| Lim, SJ | 1 |
| Jeong, IK | 1 |
| Ma, X | 1 |
| Xing, J | 1 |
| Jiao, Y | 1 |
| Muriel, P | 1 |
| López-Sánchez, P | 1 |
| Ramos-Tovar, E | 1 |
| Yu, H | 1 |
| Zhao, L | 1 |
| Du, T | 1 |
| Lin, X | 1 |
| Yu, X | 1 |
| Huang, JF | 1 |
| Yeh, ML | 1 |
| Huang, CF | 1 |
| Huang, CI | 1 |
| Tsai, PC | 1 |
| Tai, CM | 1 |
| Yang, HL | 1 |
| Dai, CY | 1 |
| Hsieh, MH | 1 |
| Chen, SC | 1 |
| Yu, ML | 1 |
| Chuang, WL | 1 |
| Katsiki, N | 3 |
| Athyros, VG | 4 |
| Karagiannis, A | 3 |
| Jaruvongvanich, V | 2 |
| Ahuja, W | 2 |
| Wirunsawanya, K | 1 |
| Wijarnpreecha, K | 3 |
| Ungprasert, P | 3 |
| Paschos, P | 1 |
| Tsimperidis, A | 1 |
| Katsoula, A | 1 |
| Grammatikos, N | 1 |
| Giouleme, O | 2 |
| Nobili, V | 3 |
| Mosca, A | 3 |
| Scorletti, E | 3 |
| Byrne, CD | 3 |
| Mann, JP | 1 |
| Armstrong, MJ | 1 |
| Darmawan, G | 1 |
| Hamijoyo, L | 1 |
| Hasan, I | 1 |
| Yu, XL | 1 |
| Shu, L | 1 |
| Shen, XM | 1 |
| Zhang, XY | 1 |
| Zheng, PF | 1 |
| Zhou, YJ | 1 |
| Zhou, YF | 1 |
| Zheng, JN | 1 |
| Liu, WY | 2 |
| Van Poucke, S | 1 |
| Zou, TT | 1 |
| Zhang, DC | 1 |
| Shen, S | 1 |
| Shi, KQ | 3 |
| Wang, XD | 1 |
| Zheng, MH | 3 |
| Zheng, X | 1 |
| Peng, B | 1 |
| Ren, W | 1 |
| Robin, S | 1 |
| Buchanan, R | 1 |
| Poole, R | 1 |
| De Vito, R | 2 |
| Raponi, M | 1 |
| Ma, L | 1 |
| Miao, M | 4 |
| Jensen, T | 2 |
| Abdelmalek, MF | 1 |
| Sullivan, S | 1 |
| Nadeau, KJ | 1 |
| Green, M | 1 |
| Roncal, C | 1 |
| Kuwabara, M | 2 |
| Sato, Y | 1 |
| Kang, DH | 1 |
| Rosen, HR | 1 |
| Diehl, AM | 1 |
| Li, TT | 2 |
| Wang, AP | 2 |
| Lu, JX | 1 |
| Chen, MY | 2 |
| Zhao, CC | 2 |
| Tang, ZH | 1 |
| Li, LX | 2 |
| Jia, WP | 2 |
| Kim, JY | 1 |
| Yang, HR | 3 |
| Wang, GE | 1 |
| Li, YF | 1 |
| Zhai, YJ | 1 |
| Tian, JY | 1 |
| Yao, N | 1 |
| Wu, YP | 1 |
| Kurihara, H | 1 |
| He, RR | 1 |
| Wójcik, M | 1 |
| Ruszała, A | 1 |
| Szczudlik, E | 1 |
| Janus, D | 1 |
| Sztefko, K | 1 |
| Starzyk, JB | 1 |
| Bai, JX | 1 |
| Shu, RM | 1 |
| Peng, Z | 1 |
| Pan, Y | 1 |
| Zhu, Z | 1 |
| Qin, S | 2 |
| Song, X | 1 |
| Liu, F | 1 |
| Troisi, J | 1 |
| Belmonte, F | 1 |
| Bisogno, A | 1 |
| Lausi, O | 1 |
| Marciano, F | 1 |
| Cavallo, P | 1 |
| Guercio Nuzio, S | 1 |
| Landolfi, A | 1 |
| Pierri, L | 1 |
| Vajro, P | 1 |
| Garcia-Arroyo, FE | 1 |
| Cicerchi, C | 1 |
| Roncal-Jimenez, CA | 1 |
| Hamid, H | 1 |
| Zhang, JY | 1 |
| Li, WX | 1 |
| Li, ML | 1 |
| Zhao, LH | 1 |
| Ji, C | 1 |
| Ma, QG | 1 |
| Kalafati, IP | 1 |
| Borsa, D | 1 |
| Dimitriou, M | 1 |
| Revenas, K | 1 |
| Kokkinos, A | 1 |
| Dedoussis, GV | 1 |
| Fernández Rodríguez, CM | 1 |
| Aller, R | 1 |
| Gutiérrez García, ML | 1 |
| Ampuero, J | 1 |
| Gómez-Camarero, J | 1 |
| Martín-Mateos, RMª | 1 |
| Burgos-Santamaría, D | 1 |
| Rosales, JM | 1 |
| Aspichueta, P | 1 |
| Buque, X | 1 |
| Latorre, M | 1 |
| Andrade, RJ | 1 |
| Hernández-Guerra, M | 1 |
| Romero-Gómez, M | 1 |
| Min, HK | 1 |
| Cho, H | 1 |
| Park, SH | 1 |
| Xu, K | 2 |
| Zhao, X | 1 |
| Fu, X | 1 |
| Cai, Z | 1 |
| Qiao, L | 1 |
| Bao, J | 1 |
| Luo, K | 1 |
| Bian, J | 1 |
| Jin, D | 1 |
| Moon, SS | 1 |
| Neuschwander-Tetri, BA | 1 |
| Xie, Y | 1 |
| Tan, A | 1 |
| Liang, Z | 1 |
| Shi, D | 1 |
| Lu, Z | 1 |
| Wu, C | 1 |
| Liao, M | 1 |
| Hu, Y | 2 |
| Li, L | 1 |
| Peng, T | 1 |
| Mo, Z | 1 |
| Cai, W | 2 |
| Zhang, B | 3 |
| Sun, YP | 2 |
| Zou, Y | 1 |
| Tian, CR | 1 |
| Qian, L | 1 |
| Du, CL | 1 |
| Shen, XZ | 1 |
| Song, JM | 1 |
| Zhang, YX | 1 |
| Sertoglu, E | 2 |
| Ercin, CN | 2 |
| Celebi, G | 1 |
| Gurel, H | 2 |
| Kayadibi, H | 2 |
| Genc, H | 1 |
| Kara, M | 1 |
| Dogru, T | 2 |
| Liu, P | 1 |
| Ma, F | 2 |
| Lou, H | 1 |
| Yoneda, M | 1 |
| Thomas, E | 1 |
| Sumida, Y | 1 |
| Imajo, K | 1 |
| Hyogo, H | 1 |
| Fujii, H | 1 |
| Ono, M | 1 |
| Kawaguchi, T | 1 |
| Eguchi, Y | 1 |
| Nakajima, A | 1 |
| Liu, PJ | 1 |
| Lou, HP | 1 |
| Zhu, YN | 1 |
| Uyanik, M | 1 |
| Sullivan, JS | 1 |
| Le, MT | 1 |
| Pan, Z | 1 |
| Rivard, C | 2 |
| Love-Osborne, K | 1 |
| Robbins, K | 1 |
| Sokol, RJ | 1 |
| Sundaram, SS | 1 |
| Schwimmer, JB | 2 |
| Zepeda, A | 1 |
| Newton, KP | 1 |
| Xanthakos, SA | 1 |
| Behling, C | 1 |
| Hallinan, EK | 1 |
| Donithan, M | 1 |
| Tonascia, J | 2 |
| Tanaka, T | 2 |
| Barabanchyk, OV | 1 |
| Svintsits'kyĭ, AS | 1 |
| Kozak, NP | 1 |
| Wan, X | 1 |
| Weng, H | 1 |
| Yan, M | 1 |
| Dooley, S | 1 |
| Liang, J | 1 |
| Pei, Y | 1 |
| Liu, XK | 1 |
| Dou, LJ | 1 |
| Zou, CY | 1 |
| Qiu, QQ | 1 |
| Yang, MQ | 1 |
| Qi, L | 1 |
| Peluso, I | 1 |
| Manafikhi, H | 1 |
| Reggi, R | 1 |
| Palmery, M | 1 |
| Shih, MH | 1 |
| Lazo, M | 1 |
| Liu, SH | 1 |
| Bonekamp, S | 1 |
| Hernaez, R | 1 |
| Clark, JM | 1 |
| Zelber-Sagi, S | 2 |
| Ben-Assuli, O | 2 |
| Rabinowich, L | 2 |
| Goldstein, A | 1 |
| Magid, A | 1 |
| Shalev, V | 2 |
| Shibolet, O | 2 |
| Chodick, G | 2 |
| Wu, SJ | 2 |
| Zhu, GQ | 2 |
| Ye, BZ | 1 |
| Kong, FQ | 1 |
| Zheng, ZX | 1 |
| Zou, H | 1 |
| Lin, L | 1 |
| Braddock, M | 2 |
| Huang, WJ | 1 |
| Chen, YP | 1 |
| Nakatsu, Y | 2 |
| Seno, Y | 1 |
| Kushiyama, A | 2 |
| Sakoda, H | 2 |
| Fujishiro, M | 2 |
| Katasako, A | 1 |
| Mori, K | 2 |
| Matsunaga, Y | 2 |
| Fukushima, T | 1 |
| Kanaoka, R | 1 |
| Yamamotoya, T | 2 |
| Kamata, H | 1 |
| Asano, T | 2 |
| Kargiotis, K | 1 |
| Katsiki, E | 1 |
| Anagnostis, P | 1 |
| Boutari, C | 1 |
| Doumas, M | 1 |
| Mikhailidis, DP | 2 |
| Agilli, M | 1 |
| Aydin, FN | 1 |
| Yuan, H | 1 |
| Sun, L | 1 |
| Zhu, X | 1 |
| Zhao, C | 1 |
| Que, S | 1 |
| Zhu, WH | 1 |
| Fang, LZ | 1 |
| Lu, CR | 1 |
| Dai, HL | 1 |
| Chen, JH | 1 |
| Qiao, QH | 1 |
| Chen, LY | 1 |
| Sun, DQ | 1 |
| Lu, QD | 1 |
| Song, D | 1 |
| Xia, M | 1 |
| Wang, D | 2 |
| Zhao, N | 1 |
| Pan, B | 1 |
| Gao, X | 2 |
| Gong, S | 1 |
| Jia, G | 1 |
| Di, F | 1 |
| Shao, J | 1 |
| Gao, L | 1 |
| Kanbay, M | 1 |
| Solak, Y | 1 |
| Le, M | 1 |
| Chang, EJ | 2 |
| Yi, DY | 1 |
| Wei, F | 1 |
| Ozcelik, F | 1 |
| Yiginer, O | 1 |
| Fukuno, H | 1 |
| Muguruma, N | 1 |
| Lu, ZY | 1 |
| Li, YL | 2 |
| Wulasihan, M | 2 |
| Lombardi, R | 1 |
| Pisano, G | 1 |
| Fargion, S | 1 |
| Panahi, Y | 2 |
| Kianpour, P | 1 |
| Mohtashami, R | 1 |
| Jafari, R | 1 |
| Simental-Mendía, LE | 1 |
| Yu, TP | 1 |
| Bao, YQ | 1 |
| Musha, H | 1 |
| Xing, Y | 1 |
| Mei, CX | 1 |
| Wang, HJ | 1 |
| Fan, N | 1 |
| Xia, Z | 1 |
| Peng, L | 1 |
| Peng, Y | 1 |
| Wei, TY | 1 |
| Wang, CC | 1 |
| Zhou, Z | 1 |
| Song, K | 1 |
| Zhou, H | 1 |
| Guo, Z | 1 |
| Dong, C | 1 |
| Bai, Y | 1 |
| Feng, F | 1 |
| Liang, S | 1 |
| Song, R | 1 |
| Panjawatanan, P | 1 |
| Lekuthai, N | 1 |
| Thongprayoon, C | 1 |
| Cheungpasitporn, W | 1 |
| Liu, CQ | 1 |
| He, CM | 1 |
| Chen, N | 1 |
| Zeng, X | 1 |
| Yan, B | 1 |
| Liu, S | 1 |
| Ueda, K | 1 |
| Inoue, Y | 1 |
| Ono, H | 1 |
| Crudele, A | 1 |
| Villani, A | 1 |
| Alisi, A | 1 |
| Huang, F | 1 |
| Liu, A | 1 |
| Fang, H | 1 |
| Geng, X | 1 |
| Kuo, CF | 1 |
| Yu, KH | 1 |
| Luo, SF | 1 |
| Chiu, CT | 1 |
| Ko, YS | 1 |
| Hwang, JS | 1 |
| Tseng, WY | 1 |
| Chang, HC | 1 |
| Chen, HW | 1 |
| See, LC | 1 |
| Hwang, IC | 1 |
| Suh, SY | 1 |
| Suh, AR | 1 |
| Ahn, HY | 1 |
| Petta, S | 1 |
| Cammà, C | 1 |
| Cabibi, D | 1 |
| Di Marco, V | 1 |
| Craxì, A | 1 |
| Vos, MB | 1 |
| Colvin, R | 1 |
| Belt, P | 1 |
| Molleston, JP | 1 |
| Murray, KF | 1 |
| Rosenthal, P | 1 |
| Unalp, A | 1 |
| Lavine, JE | 1 |
| Kubes, P | 1 |
| Mehal, WZ | 1 |
| Xia, MF | 1 |
| Lin, HD | 1 |
| Li, XM | 1 |
| Yan, HM | 1 |
| Bian, H | 1 |
| Chang, XX | 1 |
| He, WY | 1 |
| Jeekel, J | 1 |
| Hofman, A | 1 |
| Sirota, JC | 1 |
| McFann, K | 1 |
| Targher, G | 1 |
| Chonchol, M | 1 |
| Jalal, DI | 1 |
| Ghamarchehreh, ME | 1 |
| Beiraghdar, F | 1 |
| Zare, R | 1 |
| Jalalian, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis[NCT01068444] | Phase 2 | 90 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver Disease[NCT05474560] | Phase 4 | 90 participants (Actual) | Interventional | 2022-01-01 | Completed | ||
| The Effect of Dietary Fructose on Gut Microbiota and Hepatosteatosis in Healthy Men[NCT04898621] | 58 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| Genetic-specific Effects of Fructose on Liver Lipogenesis[NCT03783195] | 15 participants (Actual) | Interventional | 2019-01-25 | Completed | |||
| A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels Among Generally Healthy Participants[NCT03175757] | 33 participants (Actual) | Interventional | 2017-05-12 | Completed | |||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| Effects of 4-month Therapy of Levothyroxine on Non-Alcoholic Fatty Liver Disease (NAFLD) and Diabetes Control in Diabetic Patients[NCT03281083] | Phase 2 | 29 participants (Actual) | Interventional | 2014-03-28 | Terminated (stopped due to Difficult recruitment and end of funding.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for uric acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The contribution of sterile inflammation to the fatty liver disease and the potential therapies.
Topics: Adenosine Monophosphate; Alarmins; Caspase 1; Guanosine Monophosphate; Humans; Inflammation; Inflamm | 2022 |
Fructose Production and Metabolism in the Kidney.
Topics: Animals; Cardiomegaly; Diabetic Nephropathies; Dietary Sugars; Energy Metabolism; Fatty Acids; Fruct | 2020 |
Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review.
Topics: Biomarkers; Humans; Hyperuricemia; Liver; Non-alcoholic Fatty Liver Disease; Uric Acid | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Fructose and the Liver.
Topics: Animals; Fructose; Humans; Inflammation; Liver; NLR Family, Pyrin Domain-Containing 3 Protein; Non-a | 2021 |
Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia.
Topics: Arthritis, Gouty; Carotid Artery Diseases; Gout; Humans; Hyperuricemia; Kidney; Non-alcoholic Fatty | 2017 |
Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Topics: Adult; Biomarkers; Biopsy; Chi-Square Distribution; Female; Humans; Hyperuricemia; Liver; Male; Midd | 2017 |
Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Topics: Allopurinol; Atorvastatin; Biomarkers; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductas | 2018 |
Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Severity of Illness Index; Uric Acid | 2017 |
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Topics: Animals; Beverages; Carbonated Beverages; Eating; Fructokinases; Fructose; Gastrointestinal Microbio | 2018 |
Carbohydrate intake and nonalcoholic fatty liver disease.
Topics: Animals; Beverages; Clinical Trials as Topic; Dietary Carbohydrates; Fatty Liver; Fibrosis; Humans; | 2013 |
Effects of red wine on postprandial stress: potential implication in non-alcoholic fatty liver disease development.
Topics: Antioxidants; Biomarkers; Humans; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Postprandial | 2015 |
Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Male; Metabolic Syndrome; Middle | 2015 |
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies.
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fat | 2015 |
Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.
Topics: Animals; Drug Design; Humans; Hyperuricemia; Inflammasomes; Insulin Resistance; Metabolic Syndrome; | 2016 |
Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; Female; Humans; Hyperuricemia; Male; Middl | 2016 |
Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.
Topics: Animals; Cross-Sectional Studies; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Prevalen | 2016 |
Uric acid in metabolic syndrome: From an innocent bystander to a central player.
Topics: Diabetes Mellitus; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Non-alcoholic Fatty Live | 2016 |
High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Topics: Biomarkers; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2016 |
[Studies on association between nonalcoholic fatty liver disease and hyperuricemia: current status and future prospects].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Non-alcoholic Fatty | 2016 |
Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD.
Topics: Disease Progression; Ferritins; Humans; Liver Cirrhosis; Metabolic Syndrome; Non-alcoholic Fatty Liv | 2016 |
Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis.
Topics: Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2017 |
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis.
Topics: Animals; Atherosclerosis; Disease Progression; Free Radicals; Heart Failure; Humans; Inflammasomes; | 2016 |
Serum uric acid levels in non-alcoholic steatosis patients: a meta-analysis.
Topics: Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Sensitivity and Sp | 2017 |
Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Topics: Biomarkers; Chi-Square Distribution; Humans; Hyperuricemia; Liver Cirrhosis; Non-alcoholic Fatty Liv | 2017 |
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
Topics: Cardiovascular Diseases; Chronic Disease; Evidence-Based Medicine; Fatty Liver; Humans; Hyperuricemi | 2011 |
Sterile inflammation in the liver.
Topics: Acetaminophen; Adenosine Triphosphate; Caspase 1; Chemical and Drug Induced Liver Injury; Chemotaxis | 2012 |
7 trials available for uric acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Citrus Bergamia and Cynara Cardunculus Reduce Serum Uric Acid in Individuals with Non-Alcoholic Fatty Liver Disease.
Topics: Citrus; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2022 |
Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Elasticity Imaging Techniques; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Dise | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Topics: Adult; Biomarkers; Biopsy; Blood Glucose; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductas | 2015 |
Liver Fat Content Is Associated with Elevated Serum Uric Acid in the Chinese Middle-Aged and Elderly Populations: Shanghai Changfeng Study.
Topics: Adipose Tissue; Aged; Aging; China; Female; Humans; Hyperuricemia; Liver; Male; Middle Aged; Non-alc | 2015 |
Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Curc | 2016 |
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases; | 2012 |
138 other studies available for uric acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study.
Topics: Adult; Body Mass Index; Cholesterol, HDL; Humans; Non-alcoholic Fatty Liver Disease; Triglycerides; | 2021 |
Sesamol supplementation alleviates nonalcoholic steatohepatitis and atherosclerosis in high-fat, high carbohydrate and high-cholesterol diet-fed rats.
Topics: Animals; Aorta; Atherosclerosis; Benzodioxoles; Cholesterol, Dietary; Diet, High-Fat; Dietary Carboh | 2021 |
The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients.
Topics: Cardiovascular Diseases; Humans; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Risk Factors; | 2022 |
A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study.
Topics: Alanine Transaminase; D-Alanine Transaminase; Humans; Non-alcoholic Fatty Liver Disease; Risk Factor | 2022 |
Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients.
Topics: Chronic Disease; Gout; Gout Suppressants; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2023 |
Association between circulating cystatin C and hyperuricemia: a cross-sectional study.
Topics: Aged; Cross-Sectional Studies; Cystatin C; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; | 2022 |
Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease: A 2-Sample Bidirectional Mendelian Randomization Study.
Topics: Genome-Wide Association Study; Humans; Mendelian Randomization Analysis; Non-alcoholic Fatty Liver D | 2022 |
The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population.
Topics: Cross-Sectional Studies; Female; Gout; Humans; Male; Non-alcoholic Fatty Liver Disease; Renal Insuff | 2022 |
Higher serum uric acid to HDL-cholesterol ratio is associated with onset of non-alcoholic fatty liver disease in a non-obese Chinese population with normal blood lipid levels.
Topics: Body Mass Index; China; Cholesterol; Cholesterol, LDL; Humans; Lipids; Metabolic Syndrome; Non-alcoh | 2022 |
The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population.
Topics: Creatinine; Cross-Sectional Studies; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Nutrit | 2023 |
Conjunctional Relationship between Serum Uric Acid and Serum Nickel with Non-Alcoholic Fatty Liver Disease in Men: A Cross-Sectional Study.
Topics: China; Cross-Sectional Studies; Humans; Male; Nickel; Non-alcoholic Fatty Liver Disease; Prospective | 2022 |
Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States.
Topics: Creatinine; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Humans; Male; Non-alcoho | 2022 |
Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence.
Topics: Body Mass Index; Cholesterol, LDL; Female; Humans; Incidence; Male; Non-alcoholic Fatty Liver Diseas | 2022 |
Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease.
Topics: Cardiovascular Diseases; Humans; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Uric Acid | 2023 |
The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease.
Topics: Cross-Sectional Studies; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Ultrasonography; U | 2022 |
Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
Topics: Adolescent; Child; Glucagon; Glucose; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non- | 2022 |
Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats.
Topics: Adenosine Deaminase; Animals; Antiretroviral Therapy, Highly Active; Caspase 3; Liver; Male; Non-alc | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Mild methylenetetrahydrofolate reductase deficiency accelerates liver triacylglycerol and uric acid accumulation in fructose-fed mice.
Topics: Animals; Fructose; Liver; Male; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57 | 2022 |
Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypertension; Kidney Diseases; Ma | 2023 |
The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study.
Topics: Gout; Humans; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Risk Factors; Uric Acid | 2023 |
Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population.
Topics: Body Mass Index; East Asian People; Humans; Hyperuricemia; Metabolic Syndrome; Non-alcoholic Fatty L | 2023 |
Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study.
Topics: Adult; Body Mass Index; China; Cross-Sectional Studies; East Asian People; Female; Humans; Hyperuric | 2022 |
[Clinical significance of ultrasound combined with serological indexes for predicting nonalcoholic fatty liver disease in patients with chronic hepatitis B with normal or slightly elevated alanine aminotransferase].
Topics: Alanine Transaminase; Biopsy; Clinical Relevance; Hepatitis B, Chronic; Humans; Liver; Liver Cirrhos | 2022 |
Noninvasive assessment of paediatric hepatic steatosis by using attenuation imaging.
Topics: Adolescent; Bayes Theorem; Child; Female; Humans; Liver; Male; Non-alcoholic Fatty Liver Disease; Ob | 2023 |
Uric acid and sCD163 as biomarkers for metabolic dysfunction and MAFLD in children and adolescents with overweight and obesity.
Topics: Adolescent; Biomarkers; Child; Cross-Sectional Studies; Humans; Non-alcoholic Fatty Liver Disease; O | 2023 |
Positive correlation between fatty liver index and hyperuricemia in hypertensive Chinese adults: a H-type hypertension registry study.
Topics: Adult; East Asian People; Female; gamma-Glutamyltransferase; Humans; Hypertension; Hyperuricemia; Ma | 2023 |
Association of serum uric acid with hepatic steatosis detected by controlled attenuation parameter in the United States population.
Topics: Elasticity Imaging Techniques; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Nutrition Su | 2023 |
Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Topics: Animals; Antioxidants; Atherosclerosis; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Lipids; Non-a | 2023 |
Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.
Topics: China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Middle Aged; Non-alcoholi | 2023 |
The correlation between NAFLD and serum uric acid to serum creatinine ratio.
Topics: Adult; C-Reactive Protein; Creatinine; Humans; Non-alcoholic Fatty Liver Disease; Risk Factors; Ultr | 2023 |
[Association between metabolism-related chronic disease combination and prevalence of non-alcoholic fatty liver disease in community residents in Shanghai].
Topics: Adult; Body Mass Index; China; Chronic Disease; Diabetes Mellitus; Female; Gout; Humans; Hyperlipide | 2023 |
Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
Topics: Adult; Female; Humans; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Obesity; Overweight | 2023 |
FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning.
Topics: Cross-Sectional Studies; Elasticity Imaging Techniques; Humans; Liver Cirrhosis; Metabolic Syndrome; | 2023 |
Association of neck circumference-related indices with metabolic, atherogenic and liver function biomarkers in patients with non-alcoholic fatty liver disease: a cross-sectional study.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Female; Ferritins; Humans; Lipids; Male; Non-alcoholic F | 2023 |
Correlation between serum uric acid and body fat distribution in patients with MAFLD.
Topics: Abdominal Fat; Absorptiometry, Photon; Body Fat Distribution; Humans; Hyperuricemia; Non-alcoholic F | 2023 |
Serum uric acid is related to liver and kidney disease and 12-year mortality risk after myocardial infarction.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fat | 2023 |
Association between serum ferritin and uric acid levels and nonalcoholic fatty liver disease in the Chinese population.
Topics: Cohort Studies; East Asian People; Ferritins; Humans; Non-alcoholic Fatty Liver Disease; Uric Acid | 2023 |
Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Liver; Liver Cirrhosis; Male; Menopause; Middle Aged; Non | 2023 |
Spinal epidural lipomatosis is associated with liver fat deposition and dysfunction.
Topics: Adipose Tissue; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Bilirubi | 2019 |
Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Correlation of Data; Diabetes Mel | 2020 |
The Prevalence of Nonalcoholic Fatty Pancreas by Endoscopic Ultrasonography.
Topics: Adipose Tissue; Adult; Aged; Cross-Sectional Studies; Endosonography; Female; Humans; Hyperlipidemia | 2019 |
The Buckwheat Iminosugar d-Fagomine Attenuates Sucrose-Induced Steatosis and Hypertension in Rats.
Topics: Adipose Tissue; Animals; Diglycerides; Energy Intake; Fagopyrum; Gastrointestinal Microbiome; Hypert | 2020 |
Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease according to Different Menstrual Status Groups.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Logistic Models; Menstruation; Middle Aged; Non-alco | 2019 |
Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity.
Topics: Adolescent; Alanine Transaminase; Biomarkers; Blood Glucose; Body Mass Index; Case-Control Studies; | 2020 |
Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis.
Topics: Allopurinol; Animals; Antimetabolites; Diet, High-Fat; Enzyme Inhibitors; Fibroblast Growth Factors; | 2020 |
A nomogram for discrimination of non-alcoholic fatty liver disease in patients with chronic hepatitis B.
Topics: Hepatitis B, Chronic; Humans; Nomograms; Non-alcoholic Fatty Liver Disease; ROC Curve; Uric Acid | 2021 |
Exosomal miRNAs Profile in Children's Nonalcoholic Fatty Liver Disease and the Correlation with Transaminase and Uric Acid.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Child; Humans; Liver; MicroRNAs; Non-alcoholic Fa | 2020 |
Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study.
Topics: Cohort Studies; Humans; Non-alcoholic Fatty Liver Disease; Prospective Studies; Risk Factors; Uric A | 2020 |
Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; China; Cholesterol; Cross-Sectional Studies; F | 2020 |
Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.
Topics: Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Non-alcoholic Fatt | 2022 |
Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Nonobese Postmenopausal Women: A Cross-sectional Study.
Topics: Adult; Biomarkers; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Female; Humans; M | 2020 |
Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Cholesterol, HDL; Cholesterol, L | 2020 |
Hyperuricemia precedes non-alcoholic fatty liver disease with abdominal obesity moderating this unidirectional relationship: Three longitudinal analyses.
Topics: Beijing; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Uric Acid | 2020 |
Correlation between income and non-alcoholic fatty liver disease in a Chinese population.
Topics: Adipose Tissue; Adult; Aged; Alanine Transaminase; Asian People; China; Female; Humans; Income; Life | 2020 |
Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study.
Topics: Adolescent; Alanine Transaminase; Anthropometry; Blood Glucose; Body Mass Index; Child; China; Chole | 2020 |
Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease.
Topics: Body Mass Index; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Male; Non-alcoholic Fatty L | 2021 |
Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population.
Topics: China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Non-alcoholic Fatty Liver Disease | 2021 |
Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
Topics: Animals; Diet, High-Fat; Drugs, Chinese Herbal; Gastrointestinal Microbiome; Inflammation; Insulin; | 2021 |
Study on the independent effect of thyroid hormone based on uric acid level on NAFLD.
Topics: Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Risk Factors; Thyroid Hormones; Triglycerid | 2021 |
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway.
Topics: Allopurinol; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Endoplasmic | 2021 |
Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study.
Topics: Biomarkers; China; Female; Follow-Up Studies; Humans; Incidence; Longitudinal Studies; Male; Middle | 2021 |
Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Lipid Metabolism; | 2021 |
Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia.
Topics: Adult; Aged; China; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; H | 2017 |
Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients.
Topics: Adult; Biomarkers; Female; Humans; Keratin-18; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; | 2017 |
Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. Curr
Topics: Adamantane; Egypt; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Uric Acid; Vildagliptin | 2017 |
Reply to: "Fructose, uric acid and zonal differences in NASH".
Topics: Fructose; Humans; Non-alcoholic Fatty Liver Disease; Uric Acid | 2017 |
Fructose, uric acid, and zonal differences in NASH.
Topics: Adolescent; Child; Fructose; Humans; Non-alcoholic Fatty Liver Disease; Uric Acid | 2017 |
Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study.
Topics: Anthropometry; Blood Pressure Determination; China; Female; Humans; Hyperuricemia; Liver Function Te | 2017 |
NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.
Topics: Adult; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Biomarkers; Blood Glucos | 2017 |
Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults.
Topics: Adult; Area Under Curve; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Female; Hu | 2017 |
Energy drinks and adolescents - A hepatic health hazard?
Topics: Adolescent; Child; Energy Drinks; Fructose; Humans; Non-alcoholic Fatty Liver Disease; Surveys and Q | 2018 |
Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations.
Topics: Adolescent; Child; Diet; Female; Fructose; Humans; Hyperuricemia; Liver; Logistic Models; Male; Non- | 2018 |
Risk for the development of non-alcoholic fatty liver disease: A prospective study.
Topics: Abdomen; Adult; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; China; Cohort St | 2018 |
Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes.
Topics: Adult; Aged; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2018 |
Biochemical Predictors of Early Onset Non-Alcoholic Fatty Liver Disease in Young Children with Obesity.
Topics: Adolescent; Age of Onset; Anthropometry; Blood Pressure; Child; Child, Preschool; Cholesterol; Femal | 2018 |
Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism.
Topics: Animals; Apolipoproteins E; Carnitine; Diet, High-Fat; Energy Metabolism; Male; Mice; Mice, Knockout | 2018 |
Shall we diagnose metabolic syndrome in adolescents?
Topics: Adolescent; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol, HDL; Female; Humans; Insulin Re | 2018 |
[Correlation between serum uric acid and risk of new-onset nonalcoholic fatty liver disease: a 5-year observational cohort study].
Topics: China; Cohort Studies; Humans; Incidence; Non-alcoholic Fatty Liver Disease; Risk Factors; Triglycer | 2018 |
Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study.
Topics: Adult; Aged; Atrial Fibrillation; China; Cross-Sectional Studies; Female; Humans; Male; Non-alcoholi | 2018 |
Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease.
Topics: Cohort Studies; Diabetes Complications; Elasticity Imaging Techniques; Female; Humans; Liver; Male; | 2019 |
Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study.
Topics: Adult; Aged; Alanine Transaminase; China; Cross-Sectional Studies; Female; Humans; Male; Middle Aged | 2018 |
The severity of NAFLD is associated with the risk of urolithiasis.
Topics: Aged; Alcohol Drinking; Aspartate Aminotransferases; Blood Platelets; China; Electronic Health Recor | 2019 |
Salivary markers of hepato-metabolic comorbidities in pediatric obesity.
Topics: Adolescent; Biomarkers; Child; Comorbidity; Female; Glucose; Homeostasis; Humans; Insulin; Insulin R | 2019 |
Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.
Topics: Adipose Tissue; Aldehyde Reductase; Animals; Dose-Response Relationship, Drug; Enzyme Activation; Fr | 2019 |
Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model.
Topics: Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Bacteria; Cecum; Chickens; Disease Model | 2019 |
Dietary patterns and non-alcoholic fatty liver disease in a Greek case-control study.
Topics: Adult; C-Reactive Protein; Case-Control Studies; Diet; Diet Surveys; Feeding Behavior; Female; Greec | 2019 |
Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Body Mass Index; Chol | 2019 |
Pilot study: asymptomatic hyperuricemia patients with obesity and nonalcoholic fatty liver disease have increased risk of double contour sign.
Topics: Gout; Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Obesity; Pilot Projects; Ultrasonogr | 2020 |
Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study.
Topics: Adult; Animals; Female; Humans; Hyperuricemia; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver D | 2019 |
Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease.
Topics: Age Factors; Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Female; Humans; Kidney Func | 2019 |
Relationship between serum uric acid level and nonalcoholic fatty liver disease in pre- and postmenopausal women.
Topics: Adult; Alanine Transaminase; Asian People; Aspartate Aminotransferases; Body Mass Index; Cholesterol | 2013 |
Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men.
Topics: Adult; Aged; Asian People; China; Confidence Intervals; Diabetes Mellitus; Fatty Liver; Humans; Line | 2013 |
Serum uric acid levels and non-alcoholic fatty liver disease in Uyghur and Han ethnic groups in northwestern China.
Topics: Adult; Body Mass Index; China; Fatty Liver; Feeding Behavior; Female; Humans; Hyperuricemia; Life St | 2013 |
Increased catabolism of nucleic acid in nonalcoholic fatty liver disease patients of different ages.
Topics: Adult; Age Distribution; Case-Control Studies; Female; Humans; Male; Middle Aged; Non-alcoholic Fatt | 2014 |
The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population.
Topics: Adult; Aged; China; Cross-Sectional Studies; Ethnicity; Female; Health Surveys; Humans; Male; Middle | 2014 |
The relationship of serum uric acid with non-alcoholic fatty liver disease.
Topics: Adult; Anthropometry; Humans; Hyperuricemia; Male; Multivariate Analysis; Non-alcoholic Fatty Liver | 2014 |
[Relationship between normal serum uric acid levels and nonalcoholic fatty liver disease in postmenopausal women].
Topics: Aged; Female; Humans; Middle Aged; Non-alcoholic Fatty Liver Disease; Postmenopause; Retrospective S | 2014 |
Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease.
Topics: Humans; Male; Non-alcoholic Fatty Liver Disease; Uric Acid | 2014 |
Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; China; Cross-Sectional Studies; Diabetes Mellitus, Typ | 2014 |
Importance of the selected cut-offs for serum uric acid and lipids levels.
Topics: Ethnicity; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Uric Acid | 2014 |
Oral fructose absorption in obese children with non-alcoholic fatty liver disease.
Topics: Adolescent; Biomarkers; Blood Glucose; Body Mass Index; Breath Tests; Child; Eating; Female; Fructos | 2015 |
The significance of serum xanthine oxidoreductase in patients with nonalcoholic fatty liver disease.
Topics: Adult; Anthropometry; Case-Control Studies; Cross-Sectional Studies; Enzyme-Linked Immunosorbent Ass | 2014 |
Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease.
Topics: Adolescent; Blood Pressure Determination; Chi-Square Distribution; Child; Child, Preschool; Choleste | 2014 |
Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome.
Topics: Abdomen; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Asian People; Aspartate Aminotransfera | 2015 |
[CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
Topics: Adult; Allopurinol; Bile; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Cholesterol; Choli | 2014 |
Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
Topics: Adult; Animals; Carrier Proteins; Cohort Studies; Disease Models, Animal; Female; Gene Knockdown Tec | 2015 |
Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults: the Cardiometabolic Risk in Chinese (CRC) study.
Topics: Adult; Asian People; Biomarkers; China; Female; Humans; Hypertension; Male; Non-alcoholic Fatty Live | 2015 |
Association between serum uric acid and nonalcoholic fatty liver disease in the US population.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Female; Humans; Hyperuricemia; Logis | 2015 |
The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort.
Topics: Adult; Alanine Transaminase; Biomarkers; Body Mass Index; Cross-Sectional Studies; Databases, Factua | 2015 |
Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study.
Topics: Adult; Causality; China; Cross-Sectional Studies; Female; Humans; Longitudinal Studies; Male; Middle | 2015 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxosta | 2015 |
Association between serum uric acid and nonalcoholic fatty liver disease.
Topics: Fatty Liver; Humans; Liver; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2016 |
Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity.
Topics: Adult; Aged; Ankle Brachial Index; Biomarkers; Blood Glucose; Blood Pressure; Chi-Square Distributio | 2015 |
Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Albuminuria; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2015 |
Vitamin D Status and Bone Mineral Density in Obese Children with Nonalcoholic Fatty Liver Disease.
Topics: Adolescent; Adult; Body Composition; Bone Density; C-Reactive Protein; Child; Female; Humans; Insuli | 2015 |
The relationship between serum uric acid levels and the major risk factors for the development of nonalcoholic fatty liver disease.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2016 |
Uric acid in nonalcoholic fatty liver disease.
Topics: Fatty Liver; Humans; Liver; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2016 |
Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome.
Topics: Alanine Transaminase; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Mass Index; Female; Huma | 2016 |
Response to The relationship between serum uric acid levels and NAFLD.
Topics: Humans; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Uric Acid | 2016 |
Insulin resistance, body composition, and fat distribution in obese children with nonalcoholic fatty liver disease.
Topics: Abdominal Fat; Absorptiometry, Photon; Adolescent; Alanine Transaminase; Aspartate Aminotransferases | 2016 |
Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; China; Cholesterol, HDL; Cholesterol, LDL; | 2016 |
Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes.
Topics: Adult; Aged; Asian People; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans | 2016 |
Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Body Mass Index; Cholestero | 2016 |
The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Female; H | 2015 |
Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients.
Topics: Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Liver; Male; Middle | 2016 |
Uncovered issues in the association between uric acid and nonalcoholic fatty liver disease.
Topics: Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Risk Factors; Uric Acid | 2016 |
Associations between Serum Uric Acid and the Remission of Non-Alcoholic Fatty Liver Disease in Chinese Males.
Topics: Adult; Aged; Asian People; China; Comorbidity; Diabetes Mellitus; Humans; Hyperlipidemias; Hypertens | 2016 |
A rapid and high-throughput method for the determination of serum uric acid based on microarray technology and nanomaterial.
Topics: Allantoin; Biosensing Techniques; Cobalt; Enzymes, Immobilized; High-Throughput Screening Assays; Hu | 2017 |
Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents.
Topics: Adolescent; Biomarkers; Body Mass Index; Child; Cross-Sectional Studies; Female; Humans; Insulin Res | 2017 |
Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults.
Topics: Aged; Biomarkers; China; Disease Susceptibility; Female; Humans; Insulin Resistance; Life Style; Mal | 2016 |
Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
Topics: Adolescent; Child; Female; Fructose; Humans; Insulin Resistance; Logistic Models; Male; Non-alcoholi | 2017 |
Gout and risk of non-alcoholic fatty liver disease.
Topics: Adult; Aged; Body Mass Index; Cross-Sectional Studies; Fatty Liver; Female; Glomerular Filtration Ra | 2010 |
The relationship between normal serum uric acid and nonalcoholic fatty liver disease.
Topics: Adult; Fatty Liver; Female; Humans; Liver Function Tests; Logistic Models; Male; Middle Aged; Non-al | 2011 |
Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese.
Topics: Aged; Asian People; Body Mass Index; Cross-Sectional Studies; Fatty Liver; Humans; Non-alcoholic Fat | 2011 |
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.
Topics: Adult; Anthropometry; Biomarkers; Biopsy; Cohort Studies; Fatty Liver; Female; Humans; Hyperuricemia | 2011 |
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.
Topics: Adolescent; Ascorbic Acid; Child; Cross-Sectional Studies; Diet; Dietary Sucrose; Energy Intake; Fat | 2012 |
Renal function-dependent association of serum uric acid with metabolic syndrome and hepatic fat content in a middle-aged and elderly Chinese population.
Topics: Aged; Asian People; Cohort Studies; Cross-Sectional Studies; Fatty Liver; Female; Glomerular Filtrat | 2012 |
Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.
Topics: Adult; Aged; Aspartate Aminotransferases; Cholesterol, HDL; Cross-Sectional Studies; Fatty Liver; Fe | 2013 |